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Resumo
 A doença de Parkinson (PD) é uma perturbação cerebral e prolongada que se 
caracteriza pelo inclusão de corpos de Lewy (LB) e pela degeneração dos neurónios 
dopaminérgicos da substância nigra pars compacta (SNpc) até ao estriado. É a segunda 
doença neurodegenerativa mais comum e tem como principais sintomas a dificuldade em 
controlar os movimentos voluntários, movimentos lentos, tremor, rigidez, instabilidade 
postural e demência. Actualmente, a patogênese da PD não está totalmente clarificada mas 
alguns estudos têm sugerido que o envelhecimento, factores ambientais e genéticos 
desempenham um papel preponderante para o desenvolvimento da doença.
 Mais recentemente, estudos genéticos têm descrito várias mutações no gene Leucine-
Rich Repeat Kinase 2 (LRRK2) que causam PD do tipo autossómico dominante com início 
tardio sendo clinicamente impossível diferenciar da PD idiopática. De facto, as mutações no 
gene LRRK2 são responsáveis por 5-10% dos casos familiares e 1-2% dos casos esporádicos 
da PD. 
 A proteína LRRK2 é uma ampla e complexa proteína com diversos domínios exibindo 
duas principais actividades enzimáticas, GTPase e cinase. A mutação mais conhecida, 
G2019S, leva ao aumento da actividade cinase, enquanto mutações no domínio GTPase, tal 
como R1441C/G, também afectam a actividade cinase. A função biológica/patológica da 
proteína LRRK2 permanece desconhecida, mas várias evidências descrevem que esta proteína 
desempenha papéis no encurtamento das dendrites, disfunção mitocondrial, tradução proteica, 
autofagia, libertação de neurotransmissores e na endocitose de vesículas sinápticas. 
 De facto, a proteína LRRK2 tem sido descrita como uma proteína reguladora devido 
às suas interacções com elementos chave para o tráfego das vesículas sinápticas dentro da 
célula pré-sináptica tais como a proteína Rab5b, subunidades do complexo AP-2, 
glicoproteína 2A da vesícula sináptica (SV2A), NEM-sensitive factor (NSF) e a clathrin coat 
assembly protein, AP180.
 Neste projecto, culturas primárias de hipocampo de ratinhos Wild Type e LRRK2 
Knockout foram estabelecidas para estudar, via whole-cell patch clamp, o papel da LRRK2 na 
reciclagem de vesículas sinápticas e na libertação de neurotransmissores. A ausência de 
LRRK2 e a inibição farmacológica da actividade cinase da proteína LRRK2 prejudica a 
libertação de neurotransmissores, ao nível da célula pré-sináptica, devido a perturbações na 
endocitose de vesículas sinápticas. Juntamente com estas observações, o nosso estudo mostra 
que existe uma conservação evolucionária desta função fisiológica em Drosophila 
v
melanogaster e em neurónios de mamíferos. Perante isto, a LRRK2 também regula, em 
neurónios de mamíferos, a endocitose de vesículas sinápticas na célula pré-sináptica através 
de um ciclo de fosforilação da endofilina.
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Abstract
 Parkinson’s disease (PD), the second most common neurodegenerative disorder, is 
characterized by progressive degeneration of dopaminergic projections from the substantia 
nigra pars compacta (SNpc) to the striatum and presence of Lewy bodies (LBs). PD affects 
the control of voluntary  movement leading to tremor, postural imbalance, rigidity, and 
slowness of movement, depression and dementia. The pathogenesis of PD is not fully 
understood but many studies have suggested that aging, environmental factors and genetic 
susceptibility play an important role.
 Human genetics has defined several mutations in the Leucine-rich repeat kinase 2 
(LRRK2) gene as a cause of late-onset autosomal dominant PD that is clinically 
indistinguishable from idiopathic PD. LRRK2 mutations account for 5-10% of familial and 1–
2% of sporadic PD cases.
 LRRK2 is a large, complex, multidomain protein displaying kinase and GTPase 
enzymatic activities and multiple protein–protein interaction domains. The best characterized 
mutation, G2019S, leads to increased kinase activity, while mutations in the GTPase domain, 
such as R1441C/G, have been reported to influence kinase activity as well. The biological/
pathological function of LRRK2 remains to be established, but  several lines of evidence 
describe a role in decreased neurite outgrowth, mitochondrial dysfunction, increased protein 
translation, altered synaptic vesicles endocytosis and autophagy. 
 LRRK2 has been suggested as a regulatory protein by its interaction with key 
elements of synaptic vesicle trafficking within the recycling pool such as Rab5b, AP-2 
complex subunits, synaptic vesicle glycoprotein 2A (SV2A), NEM-sensitive factor (NSF) and 
clathrin coat assembly protein AP180.
 In this project different primary neuronal cultures of Wild Type (WT) and LRRK2 
Knockout (KO) mouse were established to study, via whole-cell patch clamp recordings, the 
role of LRRK2 in synaptic vesicle recycling and neurotransmitter release. The absence of 
LRRK2 and the pharmacologic inhibition of LRRK2 kinase activity impair the 
neurotransmission, at level of pre-synaptic cell by disrupting the endocytosis of synaptic 
vesicles. Together, our work shows that there is evolutionary conservation of this previously 
identified physiologic function of LRRK2 from fly to mammalian neurons. Also in 
mammalian neurons, LRRK2 regulates the endocytosis of synaptic vesicles in the pre-
synaptic cell, via an endophilin phosphorylation cycle.
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1. Introduction
 1.1. Parkinson’s Disease
 Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder 
(Alzheimer’s disease - AlzD is more common) [1, 2] and was described, for the first time, in 
1817 by James Parkinson (1755-1824) in his publication “An essay on the Shaking Palsy” [2, 
3]. The disease’s name, “Parkinson’s Disease”, is a tribute of Jean Martin Charcot 
(1825-1893), a French Neurologist, to the British Physician, some years after the discovery 
[4].
 PD is characterized by chronic and progressive neurodegenerative pathology of the 
Central Nervous System (CNS), which affects voluntary movements in approximately 1-2% 
of the population over the age of 65 years and 4-10% over the age of 80-85 years [5, 6]. The 
main symptoms are bradykinesia (slow movement), akinesia (impaired muscle movement), 
rigidity, rest tremor, loss of postural reflexes and flexed posture [4, 7], but the patients often 
also suffer from symptoms not associated with motor performance, such as depression [8], 
sleep disturbances, sexual dysfunction and dementia [8-12].
 At the pathological level, PD is characterized by degeneration of dopaminergic 
(DAergic) neurons from the substantia nigra pars compacta (SNpc) to the striatum and 
emergence of cytoplasmatic inclusion bodies, Lewy bodies (LBs)/neurites (LNs) in the 
substantia nigra (SN), latin denomination for “black substance”. This area is rich in DAergic 
neurons and plays an important role in movement (voluntary movement), in reward and 
addiction [12]. This “black substance”, due to the presence of neuromelanin, is located in 
mesencephalon, also called midbrain, and is a part of the nigrostriatal pathway  (NP) [5]. This 
pathway, as expected, is composed of DAergic neurons whose cell bodies are located in the 
SNpc and send projections to the basal ganglia and to the striatum, which is composed by the 
putamen and caudate nucleus (fig.1) [5, 7, 13]. In fact, the disease is hypothesized to start in 
striatum, because many studies show a larger degeneration of terminal nerves than cell bodies 
in SNpc, in early stages of PD [5, 7, 13].
 The pathophysiology  of PD remains elusive and for the majority of the PD cases the 
cause is uncertain [14]. An estimated 1 to 2% of PD patients have a clear familial etiology, 
exhibiting a classical recessive or dominant Mendelian mode of inheritance [7, 15] however, 
for the majority of PD patients the disease is probably caused by  a combination of age, 
genetic and environmental factors [16, 17]. Both these genetic and environmental components 
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together can lead to pathophysiological phenomena like inflammation, mitochondrial 
dysfunction, oxidative stress, protein misfolding and apoptosis [16, 17].
A) B)
Figure 1.  A) Schematic representation of NP and its constituents (purple) and reward circuit (blue). B) 
Schematic representation of the normal and of the diseased (in PD patients) NP (in red). It is composed of 
Daergic neurons whose cell bodies are located in the SNpc and their projections in the striatum (putamen and 
caudate nucleus). In PD, the NP degenerates and there is a marked loss of Daergic neurons that project to the 
putamen (dashed line) and a much more modest loss of those that project to the caudate (thin red solid line) [5].
 1.1.1. Hallmarks of Parkinson’s disease
 As mentioned earlier, the main pathological hallmarks of PD are degeneration of 
DAergic neurons from the SNpc to the striatum and appearance of cytoplasmatic inclusion 
bodies, LB and LN [7, 13]. In fact, the initial PD symptoms are accompanied by  significant 
neurodegeneration (some 70%) in SNpc, striatum, putamen and caudate nucleus, as above 
described, resulting in a strong reduction of dopamine (DA), the main neurotransmitter 
present in NP (fig.1) [5]. Nevertheless, the nigral damage is not uniform. The ventrolateral 
neurons in SNpc degenerate earlier and more severely  than dorsal neurons in SNpc, which is 
also accompanied by extensive extranigral pathology in the dorsal motor nucleus of the 
glossopharyngeal, vagal nerves (i.e. dorsal IX/X motor nucleus) of the medulla oblongata and 
other zones like the intermediate reticular zone, locus coeruleus (LC), basal forebrain, 
thalamus and amygdala, affecting many other systems such as the mesocortical DAergic 
system, noradrenergic, serotonergic, cholinergic and limbic system [12, 18-20].
 Lewy bodies (LBs) (fig.2) are abnormal aggregates of protein, including 
neurofilaments, α-synuclein (pre-synaptic protein, and major protein of these bodies), 
synphilin-1 and other components of the ubiquitin proteasome system (UPS), an important 
system in the clearance of proteinaceous complexes or misfolded proteins which are of high 
relevance for neurodegenerative diseases like Alzheimer’s, Parkinson’s and Huntington’s 
disease [12, 21]. Like PD, the name LB was given to these structures to pay tribute to the 
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neurologist Frederic Lewy (1885-1950), the first man who described these lesions in PD 
patients, in 1912 [15]. LBs appear in many regions of brain such as LC, nucleus basalis of 
Meynert (nbM), cerebral cortex, olfactory bulb, but despite extensive investigation, 
mechanisms of LB formation remain unknown [12, 20].
 
Figure 2.   Lewy bodies, in a SNpc DAergic neuron. Immunostaining with antibodies against α-synuclein and 
ubiquitin reveal that these protein are constituents of LB’s [5].
 Notwithstanding the presence in many  regions of brain, LBs have some different 
characteristics and, until today, these are not clarified completely. The LBs have, mainly, two 
forms: (1) classical, which are eosinophilic cytoplasmic inclusions with some fibrils [1] and 
(2) cortical form, where LBs are more homogeneous [12]. Therefore it is difficult to say when 
LB bodies arise or formed, because they  can appear in different stages of PD and with 
different characteristics [12].
 1.1.2. PD diagnosis
 PD diagnosis is often difficult, especially in early  stages. Early  signs and symptoms of 
the disease may  sometimes be dismissed as the effects of normal aging. In fact, the majority 
of clinical diagnoses about 40% of patients may not be diagnosed, ≈25% are misdiagnosed 
and only 75% of clinical diagnoses of PD are confirmed at autopsy [22].
 To decrease these percentages, in the last ten years, many studies have been performed 
to explain how PD initiates and progresses, however, the neuronal damage does not develop 
randomly but, rather, follows a predetermined sequence marked by characteristic changes in 
topographical extent [12]. In 2003, a study  of Braak et al., [12] was published and defines 6 
stages in PD: in the first stage, there are inclusion bodies only within the spindle-shaped 
projection neurons of the dorsal IX/X motor nucleus and/or intermediate reticular zone and in 
the second stage there is some cell death and LB formation in the LC. These stages do not 
have, yet, any consequences in the movements and hence the diagnosis is very difficult [12].
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 In the third stage, the features of stage 2 become more severe, SNpc is affected such as 
neuronal projections in the magnocellular nuclei of the basal forebrain. Notably, there is no 
indication, macroscopically detectable, of the SN depigmentation. At this stage, the cortical 
involvement is confined to the temporal mesocortex and allocortex (CA2-plexus) while the 
neocortex is unaffected. It is in this stage, that  diagnosis is possible. In stage 4, the odor 
sensory  areas of the neocortex and prefrontal neocortex are affected, there is a significant loss 
of neurons, especially in the posterior regions of the SNpc and the presence of inclusion 
bodies in the interstitial nucleus of the striatal terminals is observed [12].
 In stage 5, the disruption of olfactory areas is severe and LNs and LBs gradually 
decrease while in SN a visible loss of neurons is observed. Finally, in stage 6 there is the 
involvement of the entire neocortex and the premotor areas, the primary motor field, the first 
sensory  association and primary sensory areas usually are subjected to relatively mild 
pathological changes the first motor symptoms [12].
 1.1.3. PD treatment
 Actually, there is no treatment for this complex disorder, despite the large number of 
studies that have been done [2, 23]. The most significant advanced treatment occurred in the 
1960’s by Anthony Carlsson (133 years after discovery of disease) with the discovery that the 
DA precursor, levodopa (L-DOPA), could replenish DA and attenuate most motor symptoms 
when administered orally or intravenously [2, 23]. L-DOPA is however ineffective in treating 
dementia and in non-motor symptoms that occur in PD [2]. When L-DOPA enters the brain, it 
is metabolized in DAergic neurons and leads an increase of DA levels in presynaptic cells, in 
synaptic vesicles (SVs) and in the synaptic cleft. These features improve DA synaptic 
transmission and attenuate most motor symptoms, as described above [2, 24-26]. Normally, 
L-DOPA is co-administered with other drugs that prevent peripheral metabolism, enhancing 
the function of L-DOPA. In an advanced stage, with symptoms that can no longer be treated 
with L-DOPA, invasive surgical interventions can be made. Pallidotomy, which destroys the 
overactive globus pallidus, results in attenuation of many symptoms, that however return at a 
later stage. Alternatively, thalamotomy - which destroys part  of the thalamus - to block the 
abnormal brain activity, can be applied but with this approach the risk of cognitive and/or 
speech problems is substantial [24-26].
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 1.1.4. Risk Factors of Parkinson´s Disease
 The exact cause of PD remains unclear. In the last  century, PD was thought to result 
from environmental factors (e.g. toxins), and there were some clinical and epidemiological 
evidences that support the notion that PD occurred as a result of a neuronal infection, for 
example neuro-virulent strains of influenza A virus [2]. In addition to environmental 
influence, several studies reported genetic factors that govern PD [2]. While an exact cause of 
the disease is unknown, it is thought that  there is a conjunction of many  risk factors 
contributing to nigrostriatal dysfunction, such as increasing age, environmental and genetic 
factors [16, 17].
 Actually, it is estimated that  90% of all PD patients are sporadic/idiopathic PD but it is 
possible that in these cases some deoxyribonucleic acid (DNA) mutations are yet to be 
discovered[16, 17].
 1.1.4.1. Aging
 As the majority of PD patients are older than 65, it is widely accepted that aging is the 
largest risk of PD [4]. In fact, the percentage of affected individuals ranges from 1% after 65 
years and 5% from 85 years. Nevertheless, the number of young patients suffering from PD is 
substantial [4]. Therefore, PD is classified in juvenile PD (<21 years), early (between 21 and 
50 years) or late (>50 years) onset [4, 5]. The common aging mechanisms, contributing to 
development of the disease are still unknown but oxidative stress, inflammation, phenomena 
characteristic of aging, have been suggested to play a relevant role in PD [4, 5].
 
 1.1.4.2. Environmental factors
 In many studies, PD was shown to develop due to environmental risk factors, such as 
viruses, toxins affecting the CNS, via the postganglionic enteric neurons, during earlier stages 
of PD [4, 5]. An important trigger consists in pharmacological inhibition or alteration of some 
cell functions including complex I of the mitochondrial respiratory chain, formation of 
reactive oxygen species (ROS) and displacement of DA from vesicular stores. Among these 
compounds that alter the functions described above, there are many toxins, neurotoxins and 
herbicides such as 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), 6-
hydroxydopamine (6-OHDA) rotenone and paraquat [5].
 MPTP (fig.3A), a lipophilic compound, was discovered in the early 1980’s within a 
group of heroin addicts. The toxin derived, 1-methyl-4-phenyl-4-propionoxypiperidine 
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(MPPP) an analog of narcotic meperidine (Demerol), crosses the brain blood barrier (BBB) 
and is metabolized in glial cells and serotonergic neurons by monoamine oxidase B (MAO-B) 
into 1-methyl-4-phenylpyridinium (MPP+) [27, 28]. After cellular uptake, via dopamine 
transporter (DAT), MPP+ accumulates, preferentially, into mitochondria of DAergic neurons 
and inhibits complex I of the respiratory chain. This leads to production of ROS, disruption of 
the NP and adenosine triphosphate (ATP) depletion, suggesting a possible mechanism for 
nigral cell death (fig.3B) [5, 27, 28]. In fact, MPTP in mice has been shown to result in motor 
deficits, like as tremor, rigidity, slowness of movement, postural instability  (many symptoms 
of PD), caused by  cell death, microtubule depolymerization and α-synuclein/ubiquitin 
positive inclusions in the SNpc [5, 27, 28]. Despite the use as Parkinsonism model in rodents 
(study the molecular mechanisms of DAergic neurons) and primates (study  of novel 
therapeutics), the MPTP toxicity can be reverted. Cells lacking α-synuclein are insensitive to 
mitochondrial toxicity induced by MPP+ [29] and it  has been shown that α-synuclein could 
play  an important role in mediating MPP+ toxicity, perhaps through regulation of nitric oxide 
(NO) signaling [30] and/or by inhibition of MPP+-induced mitogen-activated protein kinase 
(MAPK) activation, that reduces autophagy  and mitochondrial impairments/degradation [31, 
32].
 A)  B)
Figure 3. A) Chemical structure of MPTP. B) Schematic pathway of action of MPTP. MPTP crosses BBB and is 
metabolized by glial MAO-B. After MPP+, into mitochondria inhibits complex I of respiratory chain [5].
 
 6-OHDA is a neurotoxin with a similar mode of action as MPTP (i.e. decreased 
mitochondrial complex I function) leading to production of ROS in catecholaminergic 
neurons [33]. Because many studies have reported an important role for mitochondrial 
dysfunction in PD, actually, MPTP and 6-OHDA are used to develop cellular and animal 
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models of PD. Nevertheless, MPTP, and 6-OHDA are not the only compounds with these 
properties [33].
 Paraquat, an herbicide (N,N’-dimethyl-4-4’-bipiridinium) that shows similarity  to 
MPP+ induces superoxide radical production (via mitochondrial dysfunction), which causes of 
DAergic neurons and locomotor dysfunction. This herbicide does not require DAT for uptake 
and oxidizes the cytosolic form of thioredoxin resulting in activated c-Jun N-terminal kinase 
(JNK) leading to caspase-3 activation and cell death [33]. The systemic administration of 
paraquat in mice leads to DAergic cell loss in the SNpc with LB appearance [34].
 Rotenone also blocks complex I of mitochondrial chain and its low-dose intravenous 
administration in rodents promotes the same consequences as paraquat [35].
 The relevance of PD models (cellular and animal), for understanding the impact of 
oxidative stress and complex I inhibition was further emphasized by the identification of point 
mutations in mitochondrial transfer RNA (tRNA) genes in the SN of PD cases [33]. In 
addition, some PARK genes are interfering with mitochondrial function, such as P-TEN 
induced putative kinase 1 (PINK1), that protects against  oxidative stress, and DJ-1 that 
prevents protein aggregation and oxidative stress [36-38]. On the other hand all the 
pharmacologic interventions that can reverse MPTP- or 6-OHDA-induced neurotoxicity have 
failed in the clinic for efficiency reasons. Hence these animals’ models are valuable 
symptomatic models but not PD pathogenic models [36-39].
 1.1.4.3. Genes Associated with Parkinson’s disease
 As previously described, the majority  of PD cases are believed to be idiopathic, but 
some cases (10%) have the influence of genetic factors, showing both autosomal dominant 
and recessive manners of inheritance [7, 16, 17]. During the last 20 years, many studies have 
showed that a substantial amount of PD cases are linked to specific gene mutations (see table 
1) [7, 16, 17]. These discoveries provide opportunities to investigate the functions of the 
proteins that play an important role in neurodegenerative cascade and consequently, allow 
studying the pathways involved in the PD pathogenesis such as protein aggregation, 
mitochondrial dysfunction and secretory pathway dysfunction [17].
 In fact, chromosomal regions (loci) have been mapped in familial PD (autosomal 
dominant/recessive manner) referred to as PARK1-16 (See table 1) [7, 40]. The main PD-
linked loci include two autosomal dominant genes, α-synuclein and Leucine-rich repeat 
kinase 2 (LRRK2), and three autosomal recessive genes, Parkin, DJ-1, and Phosphatase and 
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tensin (PTEN)-induced kinase 1 (PINK1). A mutation in a sixth gene, Ubiquitin C-terminal 
hydrolase L1 (UCH-L1) has only been found in one family and the importance of this gene in 
familial PD is still uncertain. The identification of mutations in PARK genes in families with 
hereditary forms of the disease has revolutionized the study of PD [7].
 1.1.4.3.1. Autosomal dominant genes
 PARK1/4 (α-synuclein)
 At the end of the 20th century, the PARK1 locus was mapped for the first time in an 
Italian family on chromosome 4q21 [41]. It was identified as the first locus linked to 
autosomal dominant form of PD and contains the α-synuclein gene, where some missense 
mutations A53T, A30P, E46K and G46L, that  modified the properties of the α-synuclein 
protein, were identified [41, 42].
 The gene that encodes α-synuclein protein spans 117 kb, contains 6 exons [41] and has 
been a major focus of PD genetic research because α-synuclein was found not only to govern 
rare forms of familial PD but also to be relevant for the pathology in sporadic PD [17].
Locus Chromosome Gene Mode of inheritance Phenotype
PARK1/4 4q21-q23 α-synuclein AD Classic PD and dementia
PARK2 6q25.2-27 Parkin AR-JP Slow progression and no LB
PARK3 2p13.3-2p13.1 Unknown AD Classic PD
PARK5 4q14 UCH-L1 AD Classic PD
PARK6 1q35-p36 PINK1 AR-JP Parkinsonism
PARK7 1p36 DJ-1 AR-JP Slow progression and no LB
PARK8 12p11.2-q13.1 LRRK2 AD Classic PD
PARK9 1p36 ATP13A2 AR KRS and dementia
PARK10 1p32 Unknown Trans. unknown Classic PD
PARK11 2q36-q37 GIGYF2 AD Classic PD
PARK12 Xq21-q25 Unknown Trans. unknown Classic PD
PARK13 2p12 HTRA2/OMI Trans. unknown Classic PD
PARK14 22q13.1 PLAG26 AR Parkinsonism + LB
PARK15 22q12-q13 FBXO7 AR Parkinsonism
PARK16 1q32 Unknown Trans. unknown Classic PD
- 17q21.1 MAPT Trans. unknown Parkinsonism
- 1q21 Glucocerebrosidase AD Parkinsonism + LB
- 5q23.1-q23.3 Synphilin-1 Trans. unknown Classic PD
- 2q22-q23 NR4A2/Nurr1 Trans. unknown Classic PD
Table 1.  PARK loci and the genes implicated in Parkinsonism and PD. This table describes the familial PARK 
loci (1-16) and genes shown to be associated to PD in non-familial forms. AD: autosomal dominant, AR: 
autosomal recessive, AR-JP: autosomal recessive-juvenile Parkinsonism, LB: Lewy body. Classic PD refers to 
the late- onset. KRS: Kufor-Rakeb syndrome  Adapted from Lees et al., 2009 [15].
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 α-Synuclein is a 19kDa, 140 amino acid protein and is the major structural component 
of LB, providing compelling evidence that it plays a major role in the pathogenesis of 
sporadic and familial PD [43, 44]. This unfolded protein contains three domains, the acidic 
region (carboxyl terminus), non-Aβ component (NAC), which confers the β-sheet potential 
domain and the N-terminal alpha-helical lipid binding domain, which contains 7 eleven 
residue repeats and are predicted to form amphiphilic helices conferring the propensity to 
form α-helical structures upon membrane binding. These repeats form an amphipathic helix 
upon membrane binding that allows binding to synaptic vesicles. This property suggests that 
α-synuclein is required for the formation and/or maintenance of a reserve pool of presynaptic 
vesicles [43, 44]. This binding is altered by A30P and A30T mutations that reduce this ability 
in a step in exocytosis before calcium (Ca2+)-induced fusion [17, 45-49].
 Predominantly, this protein, a member of the synuclein family proteins, which also 
include β- and γ-synuclein, is localized in presynaptic terminal of cholinergic and DAergic 
neurons, comprises 1% of total cytosolic protein but is also found, for unclear reasons, in 
erythrocytes and platelets. Originally identified as a result of its association with synaptic 
vesicles, α-synuclein lacks a transmembrane domain or lipid anchor and has been considered 
a peripheral membrane protein [50]. Indeed, α-synuclein binds to artificial membranes in vitro 
by adopting an α-helical conformation [50]. α-Synuclein also associates with axonal transport 
vesicles, lipid droplets, and yeast membranes [51]. However, α-synuclein behaves almost 
entirely as a soluble protein in brain extracts [17, 42, 45-49].
 α-Synuclein also plays a role in synaptic plasticity, chaperone mechanisms, storage, 
exocytosis and endocytosis/vesicle recycling and serves as a potential negative regulator of 
DA neurotransmission via interaction with the SNARE complex (mediates vesicle fusion/
release) [52, 53]. In PD, this protein is phosphorylated at Ser129 residue (and S87 residue) 
which leads to structure and form modifications suppressing tyrosine-hydroxylase (TH) 
activity [52, 53] improving DA storage into vesicles. This reduces the activity of DAT and has 
been shown to inhibit the exocytosis of vesicular glutamate transporter-1 (VGLUT-1) in 
glutamatergic vesicles and in neurons [6, 17, 43, 54]. Indeed, overexpression of Wild Type 
(WT) α-synuclein, and presence of A30P and A53T α-synuclein mutations cause an increase 
in levels of protein leading to aggregation and impairments in normal role of α-synuclein. 
A30P α-synuclein mutation, which abolishes the protein ability to bind to small phospholipids 
vesicles and A53T α-synuclein mutation, which impairs its association with planar lipid 
membranes bind to small phospholipids vesicles and A53T α-synuclein mutation, which 
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impairs its association with planar lipid membranes, inhibit exocytosis, endocytosis, synaptic 
transmission, leading to few symptoms relevant to PD [44, 49, 52, 53, 55-58].
 Nevertheless, it was also demonstrated, that knockout (KO) of α-synuclein causes 
impairments in neurotransmission by increasing of DA contents in the presynaptic cell and the 
in synaptic cleft [49, 52, 53, 55-57]. Therefore, loss of normal function of α-synuclein, as well 
a toxic effect of altered forms of mutant proteins impair the neurotransmission. Moreover, α-
synuclein can also leads to neuronal cell death by blockade of ER-Golgi trafficking, 
sequestering vesicle-trafficking proteins, such as Ypt1p, and interfering with its function. 
Conversely, overexpression of these proteins, in particular Ypt1p and its ortholog Rab1, can 
attenuate α-synuclein-induced toxicity [44, 59].
 A possible strategy to reduce the phosphorylation of α-synuclein at serine (Ser) 129 
and perhaps attenuate the PD symptoms is to stimulate the Phosphoprotein Phosphatase 2 A 
(PP2A), the primary Ser/threonine (Thr) phosphatase in the brain, protecting against α-
synuclein neurotoxicity [42, 60].
 Endocytosis, as described below, is considered to be particularly important in neurons 
and synaptic transmission, and a study of Kuwahara et  al., (2008) [49] described that 
overexpression of WT α-synuclein and mutants A30T and A53T inhibits AP-2 function [49]. 
AP-2 is involved in endocytosis, because this heterotetramer, composed of two large subunits, 
α and β2, and two small subunits µ2 and σ2, recruits clathrin and cargo receptors to the 
endocytic pits, which in turn are progressively invaginated and internalized into the cytosol by 
forming vesicles [49, 61]. The AP-2/endocytosis inhibition by α-synuclein is potentiated by 
A30P and A53T mutations, suggesting a link between AP-2/endocytosis function and α-
synuclein neurotoxicity. These findings raise the possibility  that accumulation of WT α-
synuclein or mutated α-synuclein perturbs the endocytic pathway (fig.4A) [49, 61]. 
Furthermore, overexpression of WT α-synuclein or A30P and A53T mutants also inhibits 
activity of phospholipase D2 (PLD2) in vitro and a similar action in vivo can result in a 
reduction of the number of vesicles available for DA storage and increase in the oxidative 
stress (fig.4B) [47]. PLD2 is a membrane-bound enzyme located in plasma and endosomal 
membranes, hydrolyzes phosphatidylcholine into lysophosphatidylcholine and phosphatidic 
acid in response to external stimuli. PLD2-derived phosphatidic acid then, recruits AP-2 and 
triggers the budding of vesicles from donor membranes. Thus, it  is also possible that α-
synuclein inhibits endocytosis by negatively regulating PLD2 activity [49] which is 
accompanied by the genomic multiplication of the complete α-synuclein gene, found on 
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PARK4 in other families around the world (French, Spanish, American, Japanese families). 
This gene multiplication was linked to familial PD and, actually, there is a direct relationship 
between gene dosage (protein synthesis) and disease age at onset, disease progression and 
phenotypic severity [62, 63]. As described, α-synuclein pathology in PD is not  confined to the 
cell soma, but is also prominent in neuritic processes, it is widespread in various regions of 
brain in PD and it is present in a number of other synucleinopathies such as multiple-system 
atrophy  (MSA), dementia with LB (DLBs), many  cases of AlzD (the so-called LB variant of 
AlzD), neurodegeneration with brain iron accumulation (NBIA) type 1, pure autonomic 
failure (PAF) and even a subtype of essential tremor [62, 63].
A)
B)
Figure 4. Possible models of toxic effect of α-synuclein. A) α-Synuclein may inhibit endocytosis at the 
presynaptic terminals or cell bodies [49]. B) DA is synthesized in the cytoplasm and immediately sequestered 
into synaptic vesicles. If unstored, dopamine can auto-oxidize to dopamine–quinone or 3,4-
dihydroxyphenylacetic acid (DOPAC). α-Synuclein is highly enriched in presynaptic terminals. α-Synuclein 
might be to regulate the formation of synaptic vesicles from early endosomes through interactions with PLD2. 
Mutations in α-synuclein might result in a reduced number of vesicles being available for dopamine storage, 
leading to an accumulation of dopamine in the cytoplasm and increased levels of oxidative stress [47].
 PARK5 (Ubiquitin C-terminal hydrolase L1)
 The PARK5 locus contains a gene for an autosomal dominant  form of PD and was 
mapped on chromosome 4p14 [64]. This gene encodes the enzyme Ubiquitin C-terminal 
hydrolase L1 (UCH-L1) that has a function on UPS (hydrolyses polymeric ubiquitin chains 
into monomers) and plays an important role in the regulation of synaptic function and 
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plasticity [64]. Moreover, this protein is suggested as Ubiquitin ligase enzyme (E3) ligase like 
Parkin protein (described below) that may control the ubiquitin ligase activity  dimerization-
dependent and may maintain the ubiquitin homeostasis through ubiquitin monomer stability 
[64]. In 1998, a single missense mutation in the UCH-L1 gene was identified to cause 
autosomal-dominant PD that causes the UCH-L1 aggregation in LB [65, 66].
 
 PARK8 (Leucine-rich repeat kinase 2 or dardarin - LRRK2)
 PARK8 locus was originally identified early of XXI century in a Japanese family  with 
autosomal dominant PD, the Sagamihara kindred, and was the second causal gene linked to 
autosomal dominant inherited PD [1, 67-69].
 The PARK8 locus is located on chromosome 12p11.2-q13.1 (chromosome 15 in 
mouse) [70] and was also identified in European/American families, therefore seems be 
relatively common throughout the world [71, 72]. Strikingly, neuropathological analysis of 
Japanese patients showed loss of SNpc neurons and no LB, so called “pure nigral 
degeneration or no dementia”, whereas the European families presented signs of dementia and 
motor-neuron degeneration [2, 68, 69, 72].
 The gene responsible for PARK8 linked PD was identified as Leucine-rich repeat 
kinase 2 (LRRK2). It has 144 kb and contains 51 exons, which encodes a protein with 2527 
amino acids (286 kDa) [1, 2, 6, 7, 71-74].
 Missense mutations, such as Y1654C and R1396G, were identified in LRRK2 gene in 
British and Spanish families, respectively [75]. These and additional mutations such as 
G2019S, I2020T, R1441C/G/H, Y1699C, G2385R and I1122V mutations show clear 
segregation with PD [1, 2, 7, 17, 39, 76, 77]. The most prevalent mutation, G2019S (28% at 
59 years to 74% at 79 years)  [78], is identified in Caucasian populations of North America 
and Western Europe. Probably, this mutation derived from Arabic and/or Jewish family  and 
was spread via Northern Africa or Arabic and/or Jewish Diasporas, because the populations 
with more prevalence of G2019S LRRK2 mutation are Arab Berbers (North Africa) with 39% 
of idiopathic PD and 36% of familial PD; and Ashkenazi Jews (Jews) with 10% of idiopathic 
PD and 28% of familial PD [79, 80]. In Europe, the frequency  is higher in southern European 
countries than in northern European countries and it is rarely  seen in Asians (Chinese, Korean, 
and Indian) countries [79]. The prevalence of this mutation does not differ significantly  by 
gender [73, 79].
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 At the molecular level, the G2019S mutation increases kinase activity, suggesting that 
LRRK2-driven PD is due to deregulated enzyme function (kinase) [73, 79]. At the 
pathological level, this mutation leads an increase of cell toxicity, including frontotemporal 
lobar degeneration, corticobasal syndrome, nigral neuronal degeneration and gliosis but with 
variable intraneuronal protein inclusions and in some cases leading to AlzD [31, 81]. These 
inclusions may  contain α-synuclein-positive LB and LN tau-positive neurofibrillary tangles, 
ubiquitin-positive intranuclear and cytoplasmic inclusions [77].
 The PARK8 locus and mainly LRRK2 protein has been associated with both 
idiopathic and familial PD [1]. The interaction of LRRK2 with other PARK loci (dominant 
and/or recessive), and its implication in both synucleinopathies and tauopathies, suggests that 
it might play an important role in various pathways. Therefore, an examination of LRRK2 
biochemical properties is important for understanding the mechanisms underlying the 
disorder. In addition, kinase inhibition is an attractive strategy that has the potential to lead to 
therapeutics [73, 82].
 Other loci have been linked to autosomal-dominant PD such as the PARK3 locus, 
present on chromosome 2p13, where the responsible gene leading to an autosomal dominant 
form of PD with a late onset and formation of LB was not yet identified [83] and PARK11 
locus, present on chromosome 2q36-q37 that  contains GIGYF2 gene and where the mutation 
N457T seems to be related with PD appearance [84].
 1.1.4.3.2. Autosomal recessive PD genes
 PARK2 (Parkin)
 Another gene linked to PD is PARK2 (Parkin) [64]. In 1997/1998, this locus was 
described/mapped on chromosome 6q25.2-27 in several Japanese families with autosomal 
recessive juvenile Parkinsonism (AR-JP) [17, 85, 86]. Patients that carry mutations in this 
gene have manifested PD symptoms at 20 years of age, becoming mutations in this gene the 
most common cause of early-onset Parkinsonism [85, 87]. In fact meta‐analysis of parkin 
mutation carriers suggests that pathogenic alterations to parkin gene account for up to 50% of 
AR-JP in some populations [88].
 The Parkin gene contains 12 exons encompassing 1,38Mb. This gene encodes the 
Parkin protein with 465 amino acids [85] that contains ubiquitin-like (Ubl) domain in its NH2-
terminus and a COOH-terminal cysteine-rich region that included a motif similar to a RING. 
Later, it  was established that the COOH-terminal region contains two RING fingers, 
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characterized by  the signature C3HC4 (that is, three conserved cysteine residues followed by 
a conserved histidine and then four additional conserved cysteines) plus an intermediate, 
cysteine-rich region (characterized by a C6HC pattern), that was called IBR or DRIL domain 
[86]. Actually, this characteristic protein structure is called as RBR domain [85, 87].
 Parkin protein is expressed in multiple tissues and particularly in different regions of 
the brain, including SN. These findings suggest that parkin function is normally  required for 
long-term survival of DAergic neurons although it is likely  to have functions in other tissues 
as well. This protein is responsible for transferring activated ubiquitin molecules to substrates 
targeted for degradation by the UPS, i.e., recognizes the specific protein to be ubiquitinated 
and catalyzes the transfer of ubiquitin from E2 (ubiquitin-conjugating enzyme) to this target 
protein [85, 87]. These specific proteins (targets) such as α-synuclein, synphilin-1, cyclin E, 
synaptotagmin and parkin itself are degraded in the proteasome, a component of the UPS that 
cleaves proteins in amino acids in 3 steps, as shown in figure 5 [85, 87].
Figure 5. Parkin substrates and the ubiquitin-proteasome system. Ubiquitin (red) is first activated by the E1 
(ubiquitin-activating) enzyme. Then it is transferred to the ubiquitin conjugating enzyme (E2). From E2, 
ubiquitin is finally added to the substrate of a ubiquitin protein ligase (E3), in this case Parkin. Polyubiquitinated 
substrates bind to the proteasome and are degraded, liberating short peptides and free ubiquitin, ready to be used 
again [86].
 
 In the cell, the Parkin protein appears in the cytoplasm membranous organelles, like 
endoplasmatic reticulum (ER) and Golgi apparatus, vesicular structures of dendrites and nerve 
terminals suggesting that this protein modulates trafficking of synaptic proteins such as 
endophilin-A1, an endocytic protein with a N-terminal BAR domain that  interacts with 
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amphiphysin to regulate lipid membrane curvature [87]. Therefore, some modifications in this 
protein lead to alterations in synaptic function [17].
 After mutations in LRRK2, the second most  common genetic cause of Parkinsonism 
and PD are found throughout the Parkin protein [79]. Some of these mutations are C289G, 
R275W, R256C, R334C, C431F in RING domain and R33Q, R42P, V56E and N52MfsX29 in 
the Ubl domain [87]. These mutations confer either a decreased ubiquitin ligase activity  or 
disrupt its localization, solubility or interactions with substrates such as loss of the C-
terminus, a common truncation of Parkin. This loss reduces its localization to the post-
synaptic cell, reduces the scaffold and reduces ubiquitination of Parkin post-synaptic 
substrates [17, 87]. Thus target proteins and organelles cannot be degraded and are 
accumulated in the cell ultimately leading to PD features. Although synucleinopathy is not a 
typical feature of AR-JP in humans [89], LB has been observed in some cases [17, 86, 89, 90].
 The Parkin protein is also responsible for mitochondrial maintenance and might 
induce subsequent autophagy  of dysfunctional mitochondria [17, 91]. Several mice models 
demonstrated nigrostriatal synaptic deficits, mitochondrial dysfunction and deficits in learning 
in Parkin mutants. However these phenomena are not associated with nigral DAergic cell loss 
[85, 89, 92].
 In addition, Parkin has been suggested to bind DNA and represses the tumor 
suppressor protein p53 on a transcriptional level [86], and seems to be important to control 
calcium (Ca2+) levels in glutamatergic neurons, by regulating protein interacting with C 
kinase 1 (PICK1), a protein that is implicated in internalization activity-dependent and 
retention of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  (AMPA) receptor 
GluA2 (GluR2) subunit. Together, Parkin and LRRK2 act as a part of a complex to regulate 
glutamatergic synapse formation/elimination and/or excitatory  synapse protein trafficking and 
degradation [17, 93].
 Furthermore, in the post-synaptic compartment, Parkin has been reported to function 
as a PDZ-binding protein via its C-terminus and its association with CASK, a post-synaptic 
multidomain scaffolding protein [17], suggesting that Parkin and CASK interaction have a 
relevance for neurodegenerative disorder and protein degradation [17, 94].
 
 PARK6 (Phosphatase and tensin (PTEN)-induced kinase 1)
 In 2004, a second autosomal-recessive gene inside the PARK6 locus was identified in 
three families with early-onset autosomal-recessive PD. The P-TEN induced putative kinase 1 
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(PINK1) localized on chromosome 1p35-p36 [6, 36, 95, 96] encodes a protein that plays an 
important role in regulation of mitochondrial morphology (fission and fusion) and 
functionality by control Ca2+ efflux [36, 37].
 PINK1 is a 581 amino acid protein with a catalytic Ser/Thr kinase domain. PINK1 
protein exhibits kinase activity  in vitro and it has been hypothesized that PINK1 plays a role 
in signaling cascades between the mitochondria (maintenance of mitochondrial function) and 
the nucleus by potentiating the expression of essential proteins with protective properties [97]. 
PINK1 protein regulates mitochondrial trafficking, reduces ROS formation and facilitates 
neuroprotection, regulates mitochondrial respiration efficacy, the opening of the 
mitochondrial permeability  transition pore (MpTP), interacts with cell death inhibitors and 
chaperones [36, 37, 98]. Two candidate substrates were described for direct or downstream 
phosphorylation by  PINK1 in mitochondria. These putative substrates are the heat shock 
protein (Hsp) 75 chaperone TRAP1, a ubiquitously expressed protein with significant 
sequence homology to the HSP90AA1 family of molecular chaperones, and the protease 
HtrA2, well known for its involvement in apoptosis - release from mitochondria to promote 
cell death [98].
 PINK1 is ubiquitously expressed and is localized into mitochondria (inner 
mitochondrial membrane) and two homozygous PINK1 mutations were identified: a 
truncating nonsense mutation (W437X) and a G309D missense mutation. Its functional loss 
can be substituted by  Parkin protein, nevertheless, studies with mouse embryonic fibroblasts 
(MEFs) from PINK1 KO mice have shown that Parkin is unable to localize to the 
mitochondria, suggesting that the mitochondrial function is dependent of PINK1 presence 
[37, 98]. In flies, PINK1 loss-of-function leads to muscle and DAergic degeneration due to 
mitochondrial dysfunction, a phenotype rescued by overexpression of Parkin. Thus, PINK1 
and Parkin could act  in a common biochemical pathway. Furthermore, studies with small 
interfering RNA (siRNA)-mediated depletion of PINK1 increase the susceptibility to 
apoptotic cell death [36, 37, 98].
 PARK7 (DJ-1)
 The third most  relevant autosomal recessive PD gene was discovered in 2003 and is 
localized in locus PARK7 on chromosome 1p36 [76]. The gene was called DJ-1 and encodes 
a protein called DJ-1 protein [38]. 
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 DJ-1 gene spans 24kb and contains 8 exons while DJ-1 protein is a homodimer 
constituted by 189 amino acids. This protein is localized to both neuronal and glial cells in the 
brain and was found to be hydrogen peroxide (H2O2)-responsive, suggesting that DJ-1 protein 
represents a sensor for oxidative stress, for example, DA toxicity. It acts as an antioxidant 
(direct scavenger of ROS) and protects cell against neuronal cell death, therefore, a complete 
loss of DJ-1 function may lead to mitochondrial dysfunction and PD [99, 100]. More recently 
it was hypothesized that the DJ-1 protein is part of a novel E3 ubiquitin ligase complex 
together with parkin and PINK1. Conversely, DJ-1 protein is not  a component of LB like PD 
autosomal recessive genes mentioned above [6, 38, 99, 100].
 Other loci have been linked to autosomal-recessive PD: these include PARK9, 14 and 
15. PARK9 locus, present on chromosome 1p3 is associated with rare form of autosomal-
recessive PD and is linked to Kufor-Rakeb syndrome (KRS). KRS is a rare hereditary disease 
with juvenile onset. In addition to typical signs of Parkinson disease, affected individuals 
show symptoms of more widespread neurodegeneration, including dementia [101, 102]. This 
locus contains the ATPase Type 13A2 (ATP13A2) gene. Mutations in this gene have been 
shown to cause AR-JP and early-onset  Parkinsonism (EOP) associated with atypical features 
including dementia, pyramidal degeneration. Aggregation of this protein in endoplasmic 
reticulum causes proteasomal or lysosomal dysfunction [101]. PARK14 and PARK15 loci are 
present on chromosome 22q13.1 and 22q12-q13 respectively [103].
 
 1.1.4.3.3. Loci with hereditary transmission unknown
 Until now, there are still some loci and genes that is unclear if they  are autosomal 
dominant or recessive, but mutations in these loci have been linked to PD. Some mutations in 
the CDCP2 gene on PARK10 locus, presents on chromosome 1p32, lead to classic PD 
without LB [104]; PARK12 locus presents on chromosome Xq21-q25 shows classic PD [105] 
and variants of the HTRA2/OMI gene on PARK13 locus, present on chromosome 2p12, lead 
to classic PD with LB [106].
 Additionally, three other susceptibility  genes, Nurr1 (NR4A2) on chromosome 2q22-
q23, Synphilin-1 on chromosome 5q23.1-q23.3 and tau (MAPT), which show no linkage to 
previously described PARK loci, have been linked to families with PD [40, 106].
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 1.2 LRRK2 Protein
 The majority of PD patients are a result of complex interactions between genetic and 
environmental toxins that lead to disease, but, as previously described, a gene that seems to 
play a role in both idiopathic/sporadic PD patients and familial PD patients is LRRK2 [1].
 The LRRK2 gene, contains 51 exons and a 9kb mRNA transcript that is predicted to 
encode a 286kDa (2527-amino acids) multi-domain protein, LRRK2 [1, 2, 6, 7, 71-74].
 The LRRK2 protein is a ROCO superfamily member and there are at least 40 
members in this superfamily. These proteins are found in a variety of species including 
prokaryotes, dictyostelium, plants, metazoa and mamals but not in plasmodium and yeast. 
Three other proteins belonging to this family have been identified in humans; leucine-rich 
repeat kinase 1 (LRRK1), death-associated protein kinase (Dapk1) and malignant fibrous 
histiocytoma-amplified sequence with leucine-rich tandem repeats-1 (Masl1) [107].
LRRK2 is moderately expressed in many tissues [93], such as bone marrow, lung and 
kidney, having an important role during aging [39, 108, 109]. In fact, LRRK2 mRNA and 
protein was found in circulating in peripheral blood mononuclear cells (PBMCs) and a 
deletion of LRRK2 in mice induces cytopathological abnormalities in kidney, lung tissues 
[78, 110]. In the brain, LRRK2 mRNA and protein are expressed in neurons, astrocytes, and 
microglia. LRRK2 expression is first detected in the rodent brain by embryonic day 16 to 17 
with increasing expression during neuronal maturation and postnatal stages [78]. However, in 
situ hybridization studies indicated sites of mRNA and protein expression throughout the 
mammalian brain with highest  levels of expression detected in forebrain regions, including 
the cerebral cortex and striatum, intermediate levels observed in the hippocampus, olfactory 
tubercle and cerebellum, and low levels in the thalamus, hypothalamus and SN [39, 77, 111]. 
Despite the low expression of LRRK2 in SN, the presence of LRRK2 mRNA in the SNpc of 
PD brains is dramatically reduced compared to that observed in normal control brains, 
indicating that LRRK2 is essential to DA neurons. A possible explanation is that LRRK2 
regulates proteins involved in the synthesis or release of neurotrophins which are then 
transported, via retrograde transport, from the striatum to the SNpc [111, 112]. The apparent 
absence of LRRK2 mRNA in the SNpc, despite the detection of low protein levels in this 
region may be caused by LRRK2 mRNA and protein characteristics. LRRK2 mRNA may 
have a short half-life or be transported to distal sites in nigral DAergic neurons or the LRRK2 
protein may have a particularly long half-life in these neurons so only  small number of 
mRNA copies are required to maintain protein levels [112, 113].
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 At the subcellular level, many  reports have shown that LRRK2 (monomer) is found in 
cytoplasm (mainly in soluble state) and cytoskeleton-associated (α-tubulin; β-tubulin; 
microtubules - MTs) [114].
 LRRK2 is also able to form a dimer (~600 kDa) and is found with membrane-bound 
organelles of the secretory pathway, like ER, Golgi apparatus; structures of the endocytic 
pathway (lipid rafts, clathrin-coated endosomes and multi-vesicular endosomes) and outer 
mitochondrial membrane within the rat brain, suggesting a potential role in the formation and/
or regulation of vesicular structures [39, 77]. LRRK2 dimer is substantially enriched at the 
membrane, which coincides with elevated in vitro kinase activity  of the membrane-associated 
pool of LRRK2 compared to cytosolic LRRK2 [39, 77]. In addition to its increased kinase 
activity, an increased level of GTP binding, with decreased level of phosphorylation 
(decreased GTPase activity), was observed [115]. The decreased phosphorylation status of the 
membrane-associated LRRK2 compared to cytosolic LRRK2, suggests that phosphorylation 
at certain sites may inhibit LRRK2 activity, dimer formation, trafficking to the membrane or a 
combination of these processes [115]. The discrete localization of LRRK2 to membranous 
and vesicular structures broadly  points to a role for this protein in the biogenesis, regulation 
and/or trafficking of such lipid based structures or their associated protein components [77]. 
An unpublished observation from the De Strooper lab has demonstrated presence of LRRK2 
in synaptosomal preparations from mouse brain (Wim Mandemakers, unpublished 
observation).
 1.2.1. LRRK2 protein structure
 As mentioned earlier, LRRK2 protein contains 2 catalytic domains: a ras of complex 
proteins (Roc) GTPase domain and a kinase domain like mitogen-activated protein kinase 
kinase kinase (MAPKKK). These domains are separated by a C-terminal of Ras (COR) 
domain. Roc and COR domains are always expressed together in the same molecule 
suggesting a combined function of these domains. The kinase domain of LRRK2 is situated 
C-terminal of the COR domain, a sequence with identity to receptor-interacting protein 
kinases (RIPKs), a crucial regulator of cell survival and death, and to mixed-lineage kinases 
(MLKs), a subclass of the MAPKKK family [2]. Because LRRK2 has multiple protein-
protein interaction regions, such as a C-terminal WD40 motif, an N-terminal leucine rich 
repeats (LRR) domain, an armadillo (ARM) domain and an ankyrin (ANK)-like domain, a 
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role as a scaffolding protein contributing to the formation of multi-protein signaling complex 
has been suggested (fig. 6A) [1, 6, 73, 107].
 According to its complex structure, LRRK2 seems to function as a cell signaling 
enzyme, as a scaffolding protein and modulator of other proteins via direct interaction (fig.
6B) [1].
A)
B)
Figure 6. A) Schematic structure of LRRK2 protein and their functional domains B) Proposed models of 
LRRK2-mediated signaling based on structure/function relationship. LRRK2 acts as a kinase, small GTPase or 
scaffolding protein [1].
 
 1.2.2. Ras of complex protein (Roc) domain
 As stated above, the Roc domain is one of the ROCO family members, a group of the 
Ras superfamily of small GTPases. It is constituted by 200-250 amino acids and plays diverse 
cellular functions. Indeed, it appears to be a GTP-binding protein with functional GTPase 
activity [73, 85][65, 77]. GTPases act as molecular⁄regulatory switches in a cycle between 
guanine triphosphate (GTP) and guanine diphosphate (GDP)-bound conformations, regulated 
by guanine-exchange factors (GEFs) such as the guanine nucleotide exchange factor 
ARHGEF7 and the small GTPase CDC42 and GTPase-activating proteins (GAP) such as 
ArfGAP1. In fact, ARHGEF7 binds, as guanine nucleotide exchange factor, on dimeric GDP 
bound LRRK2. Subsequently  the GDP-GTP exchange leads to activation of intrinsic GTPase 
activity of LRRK2, which induces autophosphorylation and promotes the activation/
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phosphorylation of the kinase domain (fig.7) [116]. In human embryonic kidney 293T cell 
line (HEK293T), it was observed that overexpression of R1441C mutated LRRK2 increases 
the interaction between ARHGEF7 and GTP binding of the protein LRRK2 in comparison to 
WT, but shows a decrease in GTPase activity due impairments in cycle between GTP and 
GDP-bound conformations, nevertheless LRRK2 kinase activity is stimulated upon binding of 
GTP to the Roc domain [116]. In fact, initial studies demonstrated that GTP binding enhanced 
the kinase activity  of LRRK2, whereas abolishing GTP binding via P-loop null mutations (i.e. 
T1348N) critically impaired kinase activity [78].
Figure 7. Suggested model of the intermolecular regulation of ARHGEF7 and LRRK2. ARHGEF7 binds as 
guanine nucleotide exchange factor on dimeric GDP bound LRRK2. Subsequently the GDP-GTP exchange leads 
to activation of intrinsic GTPase activity of LRRK2, which induce autophosphorylation followed by kinase 
activation of LRRK2. LRRK2 kinase domain active recognizes different substrates among them ARHGEF7 
[116].
 Within Ras-related small GTPase superfamily  there are five subfamilies that play 
important roles in signaling pathways: Ras (regulates gene expression), Rho (controls 
cytoskeletal organization and gene expression), Rab, Sar/Arf (regulates vesicular trafficking) 
and Ran (regulates microtubule organization) [39]. The Roc domain of LRRK2 protein shows 
high sequence homology with the Rab subfamily  of Ras-related GTPases. There are at least 
60 Rab genes in the human genome and a number of Rab GTPases are conserved from yeast 
to humans. Members of this family have been implicated in subcellular targeting, mainly on 
vesicular trafficking [39]. In general, Rab GTPases differ most in their carboxyl termini and 
share a structure that  is similar to all small GTPases of Ras superfamily, consisting of six 
stranded β sheet surrounded by α-helices that form 5 loops that connect the α-helices and β-
strands, and that  harbour the elements responsible for guanine nucleotide, Mg2+ and GTP 
hydrolysis. Four of these 5 loops are conserved in Roc domains and . some studies describe 
that like other Ras-related GTPases, Rab proteins are activated by  GEFs and adopts two 
distinct conformations, GDP- and GTP-bound states [109, 116, 117].
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 These GTPases are located at the cytosolic side of membrane, where they are 
implicated in regulation of membrane traffic pathways by  facilitating vesicular trafficking and 
transport processes. In the ROC domain some mutations have been identified, such as R1441 
(R1441C/G/H), Y1699C and I1371V, that alter GTP hydrolysis (fig.8) [81, 118]. However, 
these mutations show ambiguous and sometimes conflicting results, which many times is due 
to the use of different substrates in kinase assays or may be due to different enzyme 
preparations [82].
 R1441C mutation is the second most recurrent mutation after G2019S that occurs in 
kinase domain. R1441C was first found in of North America and in a small Caucasian family. 
The R1441G mutation was first  found in Basques families and it has been found to be 
prevalent in Northern Spain while R1441H mutation has never been found to co-segregate 
with PD in a large family  but in small families or in sporadic PD patients of diverse 
ethnicities including Portuguese and Australian people [81]. These mutations decrease 
GTPase activity of LRRK2, affecting its dimerization and some studies suggest an increase in 
kinase activity but there is some controversy in that  observation. These mutations also lead to 
impairments in nigrostriatal DAergic innervation (degeneration of the nigrostriatal 
projections) [73, 118], suggesting that the poor GTPase activity contributes to LRRK2 
toxicity  [39]. More recently, an in vitro study using a recombinant Roc domain fragment of 
LRRK2 demonstrated that the R1441C mutation destabilizes the LRRK2 dimer, implying a 
potential role for altered dimerization of LRRK2 in PD pathogenesis [39, 70, 73]. As the ROC 
domain regulates LRRK2 kinase activity, mutations in this domain are expected to alter 
downstream signaling properties of LRRK2. On top of this, these mutations might affect 
dimerization, possibly  via the COR domain that acts as a molecular hinge [73, 119]. The 
kinase domain remains inactive until a change in the conformation of the activation segment 
within the large C-terminal lobe is induced by  phosphorylation. In addition to the kinase 
domain, the ROC domain is, without any doubt, an important domain of LRRK2 function, 
specially, via the strict relation to kinase activity and via its direct interaction with potential 
signaling partners [73, 119].
 
 1.2.3. C-terminal of Roc (COR) domain
 Little is known about this domain, but today it is described that the COR domain is 
always found in combination with the Roc domain and thought to regulate the activity of this 
domain. The COR domain of ROCO proteins is 300-400 amino acids and does not show 
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significant sequence homology to any domain or protein described today  [109] indicating that 
more studies are necessary to obtain a better knowledge about the function of the COR 
domain. Nevertheless, in this domain a mutation, Y1699C, was one of the first mutations to 
be identified in LRRK2 and has been shown to co-segregate with the disorder in two large 
kindreds with autosomal dominant PD [81]. This mutation is positioned at the intra-molecular 
Roc:COR interface and the Y1699C substitution strengthens the intra-molecular Roc:COR 
interaction, thereby locally  weakening the dimerization of LRRK2 at the Roc-COR tandem 
domain, resulting in decreased GTPase activity and changes in kinase activity (fig.8) [120, 
121]. Another COR domain-associated mutation is the R1628P mutation, a mutation that was 
brought in connection with AlzD in one study  [121]. The R1628 amino acid is evolutionarily 
conserved across species. Substitution of a highly basic polar arginine with proline is 
postulated to result in a conformational change in LRRK2’s secondary structure which could 
disrupt the function of the COR domain. The R1628P variant could also affect the GTP 
binding capacity, the kinase activity either directly or via its interaction with the different 
functional domains of LRRK2 or other interacting protein [81].
 1.2.4. MAPKKK domain (kinase domain)
 This catalytic domain belongs to the tyrosine kinase-like (TKL) subfamily of human 
protein kinases, whose members show sequence similarity to Ser/Thr and tyrosine (Tyr) 
kinases [73, 122]. Nevertheless, LRRK2 has the Thr as the main phosphoacceptor, when 
compared to Ser and Tyr, although peptides with Ser as the phosphoacceptor were also 
identified[123].
 In conditions of cellular stress, the MAPKKK domain of LRRK2 activates all major 
MAPK pathways that have been linked to PD - extracellular-signal regulated kinase (ERK’s), 
mainly ERK1/2 and ERK5; p38 α/β/γ/δ/ MAPKs and JNKs (MKK3⁄6 and MKK4⁄7 
phosphorylation). LRRK2 also plays an important role in alternative signaling pathways like 
TNF-α/FasL pathways and Wnt signaling pathways. In fact, post-mortem studies showed that 
ERK1/2, p38 MAPK and JNK were activated in PD brains [1, 67, 118].
 This domain itself has a very  low activity  but, together with other domains, mainly 
with WD40 and GTPase domain, it is able to mediate in vitro autophosphorylation and 
phosphorylation of the artificial substrate myelin basic protein [2]. As in other functional 
domains, PD-associated LRRK2 mutations have been described to be present in this domain. 
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Some mutations, such as G2019S and I2020T, are localized at the N-terminal border of the 
activation segment and increase kinase activity (fig.10) [39, 77].
As described above, the high prevalence of the G2019S mutation, reported in 
Ashkenazi Jews and North African Arabs, has led to the hypothesis that the mutation 
originated in the Middle East about 2000 years ago. The G2019S mutation, the most prevalent 
mutation, occurs in exon 41 of LRRK2 and substitutes glycine (Gly) to Ser [124]. It  occurs 
within the DYG hinge of the Mg2+-binding⁄activation region and is associated to symptoms 
like tremor, bradykinesia and rigidity. Furthermore, the increase of LRRK2 kinase activity 
(gain-of-function effect of mutant LRRK2) was determined with use of LRRKtide (H-Arg-
Leu-Gly-Arg-Asp-Lys-Tyr-Lys-Thr-Leu-Arg-Gln-Ile-Arg-Gln-OH) in substrate 
phosphorylation or autophosphorylation experiments [73, 123]. Based on structural modeling, 
it has been postulated that  the Gly to Ser substitution forces LRRK2 to remain in a 
constitutively active state, keeping the catalytic site open, which leads to increased kinase 
activity. The DFG⁄DYG conserved region in the active site loop region tends to create a 
flexible conformation as a result of the presence of a small Gly residue [73, 118].
The I2020T mutation was initially found in the Sagamihara family, the original large 
Japanese family which had been used to map the LRRK2 locus [81]. However, the functional 
outcome of this mutation remains controversial. Some authors defend that  I2020T mutation 
increases kinase activity, while others claim a decreased kinase activity [67, 73]. 
Nevertheless, modeling analysis of a homologous MAPKKK indicates that the isoleucine to 
the Thr substitution is not predicted to result in a conformational change in the active site of 
the enzyme but increases the ATP binding affinity, despite its lower catalytic activity 
compared with wild-type LRRK2 protein [67, 73]. This mutation, as well R1441C mutation, 
is also linked to patients that have phenotypes which are similar to idiopathic PD [81].
Figure 8. Summary about main LRRK2 pathogenic mutations and its implications. LRRK2 is a large 
multidomain and contains a Roc domain, a COR domain, a kinase domain and main protein–protein interaction 
regions, the LRR and WD40 domains. Both R1441 and Y1699 mutations decrease the GTPase activity of 
LRRK2, whereas G2019S increases kinase activity. These two activities may be related because kinase domain 
autophosphorylates the Roc domain at several sites [118].
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 1.2.5. Main interaction domains: WD40 domain, Leucine-rich repeat (LRR) 
domain, armadillo (ARM) domain and ankyrin (ANK)-like domain
 As previously  described, LRRK2 contains 7 WD40 repeats and 13 LRRs forming the 
two interaction domains and two other domains, ARM and ANK domains, until today 
unknown functions [39, 122]. The WD repeat contains a GH dipeptide (11-24 residues) from 
its N-terminus and a WD dipeptide at the C-terminus separated by a conserved core sequence. 
LRR are 20-30 residues that  contain a conserved segment, generally  with 11-13 residues. 
Both WD40 domain and LRR domain adopt circular/arch-like structure, respectively. Each 
repeat of WD40 domain contains a four-stranded, anti-parallel β-pleated sheet that potentiates 
formation of a circular form and LRR are tandem sequences that potentiate arch structure 
formation in these domains [39, 122].
 These protein domains participate in many key biochemical and biological processes 
such as hormone-receptor interactions, enzyme inhibition, cell adhesion and cellular 
trafficking, early  mammalian development, neural development, cell polarization, regulation 
of gene expression, apoptosis and regulation of cytoskeletal dynamics [39, 77]. The functional 
role of these domains is underscored by fact that mutations in these domains lead to altered 
protein-protein interactions that in turn alter LRRK2 function with pathological and biological 
consequences. Indeed mutations like T2358I, G2385R, R1067Q, S1096C and S1228T; all 
localized in the WD40 domain may alter protein interactions, the dimerization and kinase 
activity [39, 78, 122]. Within these mutations, the G2385R mutation is associated with an 
elevated rate of apoptosis and cell death under conditions of oxidative stress [81].
 
 1.2.6. Cellular functions of LRRK2
 Despite the strong genetic interaction between LRRK2 and PD, the biological/
biochemical function of LRRK2 needs to be identified. It has been shown that membrane 
targeting and dimerization of WT LRRK2 are critical biochemical mechanisms governing 
LRRK2 kinase activity. Downstream LRRK2 candidate substrates and their biological 
relevance in neuronal survival, cytoskeletal rearrangement, mitochondrial dysfunction, 
protein homeostasis, autophagy, apoptosis, neurotransmission (neurotransmitter release) and 
vesicle endocytosis is becoming identified [1, 17, 31, 39, 78, 82, 115, 125, 126]. LRRK2 has 
been shown to phosphorylate moesin at Thr-558 (Thr 558) in vitro, suggesting that this residue 
is critical to phosphorylation by  LRRK2 protein (kinase domain) in vivo. This protein is an 
actin-binding ERM (ezrin, radixin and moesin) protein that has been implicated in neurite 
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outgrowth and anchors the actin cytoskeleton to the plasma membrane. Two peptides derived 
from LRRK2, LRRKtide and Nictide [78] that are phosphorylated in the equivalent Thr 
residue present in ERM  protein, and some substrates like as 4E-binding protein (4E-BP) 1
(Thr37/46), β-tubulin (Thr107), FoxO1 (Ser319), collapsin response mediator protein-2 
(CRMP-2) and creatine kinase have been described as LRRK2 candidate substrates [2, 39, 73, 
123, 127].
 1.2.6.1. Neuronal survival, cytoskeletal rearrangement
 Many studies have suggested that cytoskeleton disruption may  contribute to PD 
pathogenesis [39, 82, 115, 128]. MT cytoskeleton is critical for the generation and 
maintenance of neuronal axons and dendrites (neuronal survival), transport  of synaptic 
vesicles and organelles along the synaptic processes, and the initiation and maintenance of 
synaptic transmission, while ERM proteins link the actin cytoskeleton with membrane 
proteins and play prominent roles in the determination of cell shape, growth, and motility [39, 
82, 115, 128, 129]. The activity of an ERM protein is regulated by the intramolecular 
interaction between the N- and C-terminal regions. This interaction leads to an “inactive” 
conformation and prevents the ERM protein from associating with other proteins, including 
filamentous actin (F-actin). The phosphorylation of a conserved Thr residue in the C-terminal 
domain of ERM  proteins blocks the intramolecular association and induces a conformational 
change to an “active” state, which allows their association with F-actin and other proteins 
[128].
 LRRK2 is physiologically  involved in cytoskeletal rearrangement because many 
studies have shown that LRRK2 associates with various cytoskeleton proteins including α/β-
tubulin via Roc domain (GTPase domain) and in a guanine nucleotide independent manner (in 
vivo studies) [78, 114], F-actin, ERM family members, and the dishevelled family proteins 
(DVL1-3), supporting that LRRK2 plays a critical role in the regulation of microtubule and 
actin dynamics, and in morphogenesis of developing neurons [39, 128]. Indeed, several 
studies using overexpression, and knockdown in cell lines; studies on KO and transgenic in 
Drosophila melanogaster, Caenorhabditis elegans and mouse models have implicated 
LRRK2 in decreased neuronal cell viability [39, 82, 115], disruption of neurite outgrowth and 
synaptic morphogenesis (through distinct substrate proteins at  the presynaptic and post-
synaptic compartments) [39, 82, 115].
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 In the presynaptic side, LRRK2 forms a complex with tubulin and the Drosophila 
melanogaster variant of vertebrate MAP1B, the MT-binding protein Futsch. This protein, 
which is required for axonal and dendritic growth during embryogenesis and for synaptic 
morphogenesis, is phosphorylated by LRRK2, which negatively regulates the presynaptic 
function of Futsch in controlling MT dynamics [39, 128]. At the post-synaptic side, LRRK2 
has been suggested to interact with 4E-BP1 affecting protein synthesis, nevertheless without 
conclusive results [130]. It is thought that when LRRK2 is mutated, these interactions cause 
defects in presynaptic MT cytoskeleton dynamics and post-synaptic protein synthesis [73, 82, 
126, 130]. LRRK2 also controls the formation and stability of MTs in the presence or absence 
of microtubule-associated proteins (MAPs), respectively [39, 128, 129]. If MAPs are present, 
LRRK2 phosphorylates MAPs promoting microtubule stabilization, but in the absence of 
MAPs, LRRK2 phosphorylates β-tubulin promoting microtubule formation. In LRRK2 
G2019S neurons, the latter phosphorylations are enhanced, and lead to defects in neurite 
outgrowth [39, 128, 129]. Indeed, overexpression of WT LRRK2 and G2019S LRRK2 mutant 
has been shown to reduce the neurite length and branching in primary neuronal cell cultures 
of rat cortical neurons, whereas LRRK2 deficiency [with use of short-harpin RNA (sh-RNA)] 
results in increased neurite length and branching [125].
 More recently a paper of Kawakami et al., (2012) [131] describes that  LRRK2 
phosphorylates tubulin-associated tau and reduces its tubulin-binding ability, whereas LRRK2 
does not phosphorylate the free tau molecule. In fact, tau has not been reportedly detected as 
the LRRK2 binding protein in other studies involving proteomic analysis, except in neurons 
of G2019S LRRK2-transgenic flies that exhibited hyperphosphorylation of tau at  Thr212, 
which was ascribed to phosphorylation by the activated GSK-3β homologue, and not to direct 
phosphorylation by LRRK2 [78, 131]. Nevertheless, in the G2019S bacterial artificial 
chromosome (BAC) transgenic mice, an increased of Tau phosphorylation has been observed 
[131].
 Other reports have shown that LRRK2 and its mutants phosphorylate ERM family 
members [128, 132]. In fact, LRRK2 modulates positively  and negatively  ERM but in 
LRRK2 G2019S neurons the numbers of phosphorylated ERM  (pERM) and F-actin enriched 
filopodia were significantly increased, which correlates with the retardation of neurite 
outgrowth in these neurons. Conversely, the levels of pERM and F-actin within the filopodia 
of LRRK2 KO neurons were significantly decreased and neurite outgrowth was promoted 
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[39, 128, 132]. These findings suggest that LRRK2 serves as a regulator of cytoskeleton 
dynamics [39, 128, 131, 132].
 
 1.2.6.2. Mitochondrial dysfunction
 Mitochondria are important cellular organelles, because they do not only have a key 
role in electron transport and oxidative phosphorylation, but are also the main cellular storage 
of free radicals, Ca2+ homeostasis and involved in cell-death pathways [133-135]. Therefore, 
impaired mitochondrial function is likely to increase oxidative stress and might render cells 
more vulnerable to this and other related processes, including excitotoxicity and apoptosis 
[133-135]. Indeed, mitochondrial dysfunction is implicated in pathophysiology of PD and 
there is evidence that Parkin, α-synuclein, DJ-1 and PINK-1 associate with mitochondrial 
function and/or dysfunction. In 2005 a study reported that cytosolic LRRK2 interacted with 
Parkin protein, but not with α-synuclein or DJ-1 [93]. Therefore, LRRK2 was suggested to be 
implicated in mitochondrial dysfunction when it is mutated [134]. LRRK2 association with 
the mitochondrial outer membrane in rodent brain is supportive evidence in this matter [133, 
136]. 
Mitochondria are dynamic organelles and undergo frequent fission (cell death 
induction) and fusion (cell protection). The process of fission and fusion is regulated by 
molecular machinery  that includes dynamin-related GTPases and WD40 repeat–containing 
proteins. Because LRRK2 combines both GTPase and WD40 domains within the same 
protein, it  could potentially  serve as a scaffold during mitochondrial fission and fusion events 
[133, 136]. Furthermore, WT LRRK2 but not Y1699C, G2019S or R1441C mutants 
attenuated H2O2-induced cell death in HEK293 cells and in SH-SY5Y cells. Further 
mechanistic research indicated that  mutations such as Y1699C, G2019S or R1441C 
compromise the inherent protective capacity of WT LRRK2 against oxidative stress via its 
inability to activate the ERK1/2 pathway [134].
 1.2.6.3. Protein homeostasis, autophagy and apoptosis
 Protein aggregation, such as LB formation, is thought to play an important role in 
neurodegeneration and PD pathogenesis [108]. As described above, in the post-synaptic side, 
LRRK2 is capable to interact with and phosphorylate 4E-BP1, a negative regulator of protein 
translation [39, 73, 126, 130]. Phosphorylation of 4E-BP1 causes its release from the eIF4E 
and relieves its inhibitory effect on translation. At least six phosphorylation sites have been 
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identified in human 4E-BP1 (h4E-BP1), including T37, T46, S65, T70, S83 and S112. A 
sequential phosphorylation of 4EBP1 in the order of T37/T46>T70>S65 has been proposed 
[130]. Although the regulatory mechanisms involved in 4E-BP phosphorylation are not fully 
understood, it appears that a combination of perhaps all phosphorylation events is required to 
dissociate 4E-BP1 from eIF4E [39, 73, 126, 130]. Although LRRK2 is not the only kinase 
that phosphorylates 4E-BP T37/T46 sites, the phosphorylation of 4E-BP1 at T37/T46 sites by 
LRRK2 prevents its inhibitory binding to elF4E and, thus, stimulates elF4E-mediated protein 
translation and increases oxidative stress-induced neurotoxicity in DA neurons [82, 126, 130]. 
LRRK2 also phosphorylates forkhead transcription factor FoxO1 at Ser 319 residue, which 
controls various cellular processes involved in cell cycle, cell death, metabolism and oxidative 
stress and regulates 4E-BP1 protein transcription [39].
In a study  published in 2009 [108], absence of LRRK2 in kidneys was shown to lead 
to impairments on autophagy-lysosomal pathways, potentiating protein aggregation, 
inflammatory responses, oxidative damage and apoptotic cell death in aged mice [108]. This 
important observation demonstrates an essential cellular function of LRRK2 during aging in 
the maintenance of protein homeostasis and, in particular, α-synuclein (main component of 
LB) through the regulation of protein degradation pathways [108]. In fact, impairment in 
neurite outgrowth induced by G2019S LRRK2 is prevented by genetic inhibition of 
autophagy components but exacerbated by rapamycin, an activator of autophagy. G2019S 
LRRK2 also promoted the accumulation of autophagic vacuoles in neuritic and somatic 
compartments of cultured neurons although it is not known whether these observations result 
from enhanced autophagy, impaired autophagic flux, or impaired fusion of autophagosomes 
with lysosomes [78]. Nevertheless, in primary neuronal cultures it was also shown that 
LRRK2, in response to cellular stress such as an accumulation of misfolded proteins, or 
oxidative stress (both of which have been implicated in PD), has an important  in apoptosis 
[39, 137]. In fact, LRRK2 interacts with the C-terminal R2 RING-finger domain of Parkin 
and in turn, Parkin interacts with the COR domain of LRRK2, enhancing the ubiquitination, 
decreasing the misfolded protein aggregation [78, 93].
 The two main pathways that can trigger programmed cell death/apoptosis are (1) the 
intrinsic pathway, which is controlled by factors that are released by mitochondria 
(cytochrome C, for example) and activate caspase-9 and (2) the extrinsic pathway, which is 
typically initiated by  cell surface “death receptors” such as tumor necrosis factor receptors 
(TNF-R) and Fas that  lead to caspase-8 activation via the death adaptor Fas-associated protein 
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with death domain (FADD) [137]. LRRK2 has been shown to interact with FADD and with 
tumor necrosis factor receptor type 1-associated death domain protein (TRADD), death 
adaptor proteins important for apoptosis activation [39, 137]. The interaction between LRRK2 
and FADD is enhanced by R1441C, G2019S, Y1699C, I2020T mutations and leads to the 
recruitment and activation of caspase-8 [137]. This observation suggests that  LRRK2, FADD, 
and caspase-8 are components of a multi-protein complex. In fact, blocking LRRK2 kinase 
function eliminates the FADD binding, decreasing apoptosis activation and provides a 
potential mechanism to prevent LRRK2-mediated neuronal death [137].
 The chaperone machinery is important to chaperone-mediated autophagy (CMA) and 
it has been described that LRRK2 interacts with many elements that are involved in CMA. 
Overexpression of WT LRRK2 and pathological mutants allows showing that the molecular 
chaperone, Hsp90 (and its co-chaperone, p50cdc37) interacts with LRRK2 [39, 67]. This 
chaperone protein may help to maintain the proper folding of LRRK2. The HSP90/p50cdc37 
chaperone complex binds to LRRK2 and may assist with the activation of other protein 
kinases. Inhibition of Hsp90 disrupts the LRRK2 and Hsp90 interaction leading to LRRK2 
degradation via UPS. Therefore, Hsp90 inhibitors are potential therapeutics against mutant 
LRRK2-induced toxicity [39]. Furthermore, LRRK2 can interact with other molecular 
chaperones like HSp60, Hsp70, and the c-terminal Hsp70 interacting protein (CHIP). The last 
one binds, ubiquitinates and promotes degradation of LRRK2 via UPS and thereby reduces 
mutant LRRK2-induced toxicity [39]. Overexpression of CHIP protects against mutant 
LRRK2-induced toxicity  and enhances ubiquitination of α-synuclein in cells [39, 138] 
whereas knockdown of CHIP exacerbates toxicity  mediate by mutant  LRRK2 via reducing 
degradation of LRRK2 proteins [39].
 
 1.2.6.4. LRRK2 in Immune System and Inflammation
 LRRK2 has been suggested, through genome-wide association studies (GWAS), as 
one of a few genes where common genetic variability underlies susceptibility to the chronic 
autoimmune Crohn’s disease and Mycobacterium leprae infection (leprosy), raising the 
possibility that variations in LRRK2 may modify immunogenic responses in PD [110, 139, 
140]. As described above, LRRK2 mRNA and protein was found in circulating in PBMCs 
such as CD19+ B cells and in CD14+ monocytes, whereas CD4+ and CD8+ T cells were 
devoid of LRRK2 mRNA. Within CD14+ the CD14+CD16+ sub-population of monocytes 
exhibited high levels of LRRK2 protein in contrast to CD14+CD16- cells. However both 
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populations expressed LRRK2 mRNA. In fact, in two recent studies, the IFN-γ increased 
LRRK2 mRNA and protein levels in monocytes concomitant with a shift  of CD14+CD16- 
cells towards CD14+CD16+ but, with LRRK2 inhibitor IN-1 (LRRK2-IN-1), this shift 
towards CD14+CD16+ was attenuated after IFN-γ stimulation [110, 141]. In fact, LRRK2-
IN-1, has been used to inhibit LRRK2 because it induces dephosphorylation of Ser 910 and 
Ser 935 in kinase domain and accumulation of LRRK2 within aggregate structures. LRRK2-
IN-1 inhibits both WT and G2019S mutant LRRK2 kinase activity with IC50 (concentration 
required to inhibit 50% of enzyme activity) values of 13 nM  and 6 nM, respectively, and 
serves as a versatile tool to pharmacologically interrogate LRRK2 biology  and study  its role 
in PD [142].
 In another study of Hakimi et al., (2011) [139] demonstrated that LRRK2 expression 
in cultured bone marrow-derived macrophages from mice is upregulated in response to 
lipopolysaccharide (LPS), a potent agonist of toll-like receptor 4 (TLR4) [139]. Therefore, 
LRRK2 might have a role in immune cells, monocyte maturation and regulation at the 
transcriptional and translational level [110, 139, 140]. In the mouse brain, LRRK2 is highly 
expressed in peripheral monocytes and macrophages, and a study  of Moehle et al., (2012) 
[140] described that LRRK2 is expressed in activated microglia, after LPS induction, and that 
LRRK2 modulates pro-inflammatory responses in these cells, like as is the case in PD. 
Interestingly, the accumulation of LRRK2 protein, which occurs during inflammatory 
signaling in primary microglia, is not accompanied by  significant changes in mRNA levels, 
suggesting important post-transcriptional regulation [140]. In these mice, they also found 
LRRK2-positive small cells in the corpus callosum of mice after an intrastriatal LPS injection 
and that LRRK2 inhibition either by RNAi knockdown or small-molecule kinase inhibitors 
like LRRK2-IN-1 and Sunitinib, attenuates pro-inflammatory signaling in response to TLR4 
activation, by attenuation of TNFα secretion and nitric oxide synthase  induction (iNOS [140].
 Thus, alterations in LRRK2 function may modify  inflammatory responses in 
neurodegenerative and infectious diseases, potentially  leading to disease initiation or 
modification of progression. Hypothetically, LRRK2 G2019S missense mutation in the kinase 
loop, may serve to exaggerate neuroinflammatory responses that predispose to 
neurodegeneration susceptibility in PD. Indeed, LRRK2 may function as a stress response 
kinase during a neuroinflammatory stimulus in the brain by facilitating signal transduction 
pathways in affected cells [110, 139-141].
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 1.2.6.5. Neurotransmission and Synaptic Vesicle Endocytosis
 In the CNS, neurons are communication specialists that convert electrical into 
chemical signals at special junctions called synapses, a term introduced by  Charles 
Sherrington. There are two types the synapses: electrical and chemical. In the electrical 
synapse the gap between pre- and post-synaptic is greatly reduced (3.5 nm) and allows, 
bidirectional, the flow of ions through junction channels [61, 143]. In chemical synapses 
(20-40 nm), an action potential induces depolarization and Ca2+ (50-100 µM) influx; the 
synaptic vesicles fuse with the plasma membrane at the active zone and release their content 
(neurotransmitters – chemical substance), a process called exocytosis, to the synaptic cleft. 
Then these unidirectional diffuse across the synaptic cleft and bind to specific receptors on the 
post-synaptic cell membrane and trigger an electrical signal [61, 144, 145]. The strength of 
both electrical and chemical synapses can be increased or diminished by cellular activity. 
However, on high-frequency stimulation, the amplitude of these responses decays rapidly, a 
conclusion that Birks and MacIntosh, primarily, and Elmqvist Quastel, subsequently  obtained 
[146]. The decay  depends of stimulation but also of the SV number, therefore, they  proposed 
that there are two distinct presynaptic stores of transmitter: a “readily releasable” fraction, 
which is rapidly  depleted at high frequencies of stimulation and a “non-readily releasable” 
fraction [146]. This idea gained strength and  actually there are three different vesicle pools 
considered: the readily releasable pool (RRP) (1-2%), the recycling pool (5-20%) and the 
reserve pool (80-90%) (fig.9) [146, 147]. The RRP localizes in the active zone and is 
immediately available upon stimulation and depleted in a few milliseconds of depolarization, 
defined by a rapid and instantaneous kinetic [146, 147]. The more scattered localized 
recycling pool is responsible for maintaining the synaptic communication in physiological 
stimulations and is depleted in a few seconds. The last pool, the reserve pool is released upon 
high frequency stimulation and is depleted in 30-60s [146, 147].
Figure 9. Classic model with three pools. The reserve pool constitutes ~80–90% of the total pool,  and the 
recycling pool is significantly smaller (~5–20%). The readily releasable pool (RRP) consists of a few vesicles 
(~1-2%) that seem to be docked and primed for release [146].
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 Even though the release of synaptic transmitters appears to be smoothly graded, it is 
actually released in discrete packages called quanta. Each quantum of transmitter produces a 
post-synaptic potential of fixed size, called the quantal synaptic potential or miniature 
excitatory post-synaptic potential (mEPSP). Normally, these small events or small potential 
differences are recording in present of of Tetrodoxin (TTX). TTX is a potent neurotoxin, 
frequently used to suppress neuronal activity  in cell culture by blockade of action potentials. 
This neurotoxin binds to the voltage-gated sodium (Na+) channels and fast Na+ channels in 
presynaptic cell, preventing the uptake of Na+ and, as consequence, the entrance of Ca2+ in 
nerve terminal. The blockade of action potential propagation impairs all the synaptic vesicle 
cycle, by decreasing the ratio of recycling SV and the fusion of synaptic vesicles derived from 
recycling and reserve pool. Nonetheless. this release is linked to spontaneous excitatory post 
synaptic currents (sEPSCs), a mixture of action potential evoked (increase of Ca2+ 
concentration) and mEPSC. These sEPSCs depend of vesicle number (N), probability  of 
release (Pr) (can depend on [Ca2+] influx, sensitivity or vesicle priming), amount of 
neurotransmitter in a vesicle and post-synaptic response to a vesicle (Q=quantal size) 
(Response = NPrQ) and each sEPSC measured is the result of AMPA- and N-Methyl-D-
aspartate (NMDA)-mediated currents (Glutamatergic-mediated responses) recording in post-
synaptic cell. These sEPSC can be suppressed by using AMPA antagonists like 2,3-
dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) (at 10-30 µM) and 
2,3-benzodiazepine (GYKI 52466) (at 20-50 µM) allowing thus the study  of inhibitory post-
synaptic currents (sIPSC) when cells are clamped at -60 mV [148].
These sEPSCs are commonly studied to gain insight into release probability, 
instantaneous frequency  (Hz), believed to be as results of presynaptic mechanisms [149], 
since the velocity of synaptic vesicle and neurotransmitter release is an indication of how the 
synaptic vesicle cycle machinery  response to boosting stimulus [149]. Other important 
parameter is peak amplitude, to gain insight in changes of receptors. The peak amplitude 
measures how the post-synaptic cell works by uptake of neurotransmitters [150, 151].
In fact, via whole-cell patch clamp is possible measure these events and study  the 
currents through multiple channels. This can be achieved by  selectively choosing the ionic 
composition of the pipette and/or the bath solution; by controlling the holding potential of the 
cell membrane; or by using different pharmacological agents that selectively  block or activate 
specific channels or channel groups [152]. To measure the currents of different channels, the 
electrode, a glass micropipette that has an open tip (diameter 1µm) and resistance around 3-5 
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MΩ, is filled with a solution (internal solution) matching the ionic composition of the bath 
solution. When the electrode is in the bath solution, current level is set to zero allowing a 
constant voltage while observing changes in current (voltage clamp), or keep  a constant 
current and observing changes in voltage (current clamp). The electrode is placed on the cell 
membrane and at this moment a small suction is applied to form a GΩ between the glass and 
the cell membrane. The cell membrane inside the electrode tip is broken by an electrical pulse 
(-600 mV, 0.100 ms) allowing access to the intracellular space of the cell [153]. The electrical 
circuit is completed with silver chloride (AgCl) wire placed in contact with the bath solution. 
The events are recorded by the amplifier through specific software.
After exocytosis, SV membrane must be retrieved from the presynaptic plasma 
membrane and recycled back to the active zone via endocytosis. This process is essential to 
preserve synaptic transmission as well as the general organization of the synapse [61, 154]. 
The first study about SV endocytosis was done by Heuser and Reese [155] and these two 
scientists found that after depolarization, using a fluid-phase cytosolic marker the terminals 
were able to label some structures, later known clathrin-coated structures [155, 156]. They 
proposed that SV fuse completely  with the plasma membrane of pre synaptic cell and then is 
retrieved by  clathrin-coated invaginations at an area outside the active zone [155, 156]. 
During the subsequent years, the hypothesis proposed by Heuser and Reese, was strengthened 
by a wide variety of other studies demonstrating for example that clathrin-coated vesicles 
isolated from brain contain synaptic vesicle proteins and that most components of the clathrin 
endocytic machinery are enriched in brain [155].
 Actually, it is known that endocytosis is involved in all of the physiologic functions 
associated with the plasma membrane because it  controls the protein and lipid composition at 
the surface, regulates signaling pathways, modulates the cell surface area, regulates the 
surface expression of proteins, brings nutrient into cells, retrieves proteins deposited after 
vesicle fusion and turns over membrane components by sending these components for 
degradation in lysosomes [61, 144]. In fact, there are two major types of endocytosis, 
pinocytosis (uptake of fluid and solutes) that occurs in all cell types and phagocytosis (uptake 
of large particles) that occurs in cells of immune system [61, 144].
 Pinocytosis of synaptic vesicles is thought to be clathrin-mediated endocytosis (CME); 
the best studied type of endocytosis [61, 144]. This process occurs constitutively in most 
mammalian cells and is important for the internalization of receptors and extracellular 
ligands, recycling of plasma membrane components, and retrieval of surface proteins destined 
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for degradation [61, 144]. CME is critical in many aspects of development as well as in 
synaptic transmission, where CME provides the recycling of synaptic vesicle proteins and 
maintains the plasma membrane architecture at the synapse [144, 145, 157]. However, there 
are other possible pathways of endocytosis both clathrin-independent and clathrin-dependent 
such as: Kiss-and-run; Bulk retrieval; CLIC/GEEC endocytic pathway; arf6-dependent 
endocytosis, flotillin-dependent endocytosis, macropinocytosis, circular doral ruffles, 
phagocytosis, and trans-endocytosis (clathrin-independent modes of retrieval); collapse of one 
and retrieval of another one from the RRP, collapse of a vesicle followed by  brief dispersal 
into a few patches and collapse followed by  complete dispersal of vesicle molecules that 
occur in different times, depending of stimulation and number of SV released (fig 10) [156].
Figure 10. Possible pathways of synaptic vesicle recycling. The speed and fidelity of the recycling process tend 
to decrease from A to F. A) Kiss-and-run. B) Collapse of one vesicle and retrieval of another one from the 
‘readily retrievable’ pool. C) Collapse and (classical) CME. D) Bulk retrieval: strong stimulation followed by 
formation of infoldings, which are broken up into vesicles by CME. E) Collapse of a vesicle followed by brief 
dispersal into a few patches, which are recovered by interaction with the CME machinery. F) Collapse, followed 
by complete dispersal of vesicle molecules. They are retrieved by CME but need endosomal sorting to be made 
into new vesicles [156].
 
 Despite the existence of different pathways to retrieve the SV, clathrin was identified 
as being the major protein making the lattice-like coat around vesicles, which were described 
as ”vesicles in a basket” [154, 158]. However, this protein does not work single-handed. 
There are a large number of proteins involved in the endocytosis process in different stages 
with different functions [136, 140]. In attachment, the table summarizes the proteins that have 
a role in CME according to function: core components, cargo-specific adaptors, inositol-5-
phosphatases, kinases, actin nucleation at clathrin-coated vesicles and other proteins with 
different functions or not clear function in CME [154].
 Through the use of FM1-43 dye and synaptoPHlorin, a pH-sensitive fluorescent 
protein, it was possible determine that CME is a slow process (1 min) and occurs in majority 
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of synapses together with the “kiss-and-run” endocytosis model (less than 2 s) in separate 
molecular mechanisms [61, 144]. The “Kiss-and-run” model allows a rapid neurotransmitter 
release through a small pore without collapsing into the plasma membrane and unlike CME 
does not allow control plasmamembrane area and retrieval of SV proteins [61, 144].
 However, when neuronal activity  increases, CME lacks the capacity  to deal with the 
additional retrieval demands placed on the nerve terminal, and activity-dependent bulk 
endocytosis (ADBE) is triggered [159]. ADBE is commonly described by large invaginations 
of plasma membrane which then fission to form endosomal-like compartments [159]. SVs can 
then bud from these bulk endosomes to the active zone and release their content [159].
 CME forms coated vesicles, referred to as clathrin-coated vesicles (CCVs) and to their 
formation, addition to clathrin, a number of other proteins have been identified for assembling 
and/or uncoating of CCVs [136]. Thus, it was proposed, in a review of Jung and Haucke 
(2007) [143] that CME can be divided in four steps: adaptor recruitment, clathrin assembly, 
fission and uncoating [143]. Notwithstanding, in 2011, a review of McMahon and Boucrot 
described the same process in 5 states by division of the first  step: Initiation/Nucleation, cargo 
selection, coat assembly, scission and uncoating [154]. In both suggestions the four major 
components of CME are proposed: clathrin, heterotetramer adaptor complexes (AP-2), 
transmembrane cargo receptors, and dynamin (fig.11) [61, 144, 154, 159].
 In the first stage (Initiation/Nucleation) of CME, there is the membrane invagination 
called a pit [154]. This clathrin-coated pit initiation was thought to be triggered by  the 
recruitment of several putative nucleation proteins such as Fes/CIP4 homology (FCH) (a short 
conserved region of around 60 amino acids first described as a region of homology between 
FER and CIP4 proteins), domain only (FCHO) 1,2 proteins, EGFR pathway substrate 15–
EPS15related (EPS15–EPS15R), intersectins, epsin and endophilin [154]. This putative 
nucleation module is thought to assemble only at the plasma membrane because its preference 
for phosphoinositol-(4,5)-bis-phosphate (PIP2). The F-BAR domain of these proteins can 
bind to very  low curvatures and its membrane-binding activity is required for progression of 
the clathrin-coated pits, suggesting a need for membrane curvature generation even before 
clathrin recruitment [154].
 In the second stage (Cargo Selection) there is a recruitment of coat/endocytic proteins 
such as the clathrin adaptor/assembly  proteins (APs) [(AP-2, dynamin, amphiphysin, and 
AP180)] by intervention of PIP2, endophilin and FCHO 1,2 proteins [61, 144, 154]. Both 
AP-2, a heterotetramer complex that mediates the recruitment of clathrin to the membrane, 
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and clathrin coat assembly protein AP180, a component of adaptor complex that links clathrin 
to coated vesicles. AP2 binds both cargo and PIP2 to induce the nucleation module at PIP2 
enriched areas, to next promote internalization. AP-2 interacts with synaptotagmin protein 
(Ca2+ sensor) and synaptic vesicle glycoprotein 2 (SV2) and AP180 interacts with 
synaptobrevin (important protein to SNARE complex formation) potentiating the 
internalization. In this step, as described above, amphiphysin is also recruited to assemble 
dynamin, a GTPase protein that will have a role downstream in the CME process [61, 144, 
154].
 In the third stage, clathrin coat assembly occurs. The clathrin triskelia are recruited 
directly  from the cytosol to sites of adaptor concentration on the membrane to help organize 
the coated vesicle formation. AP-2 (mainly) and AP180 with help of regulatory proteins, such 
as Eps15, epsin and endophilin (BAR domain and SH3 domain) assemble individual clathrin 
molecules into regular cage (polymerization) in a process that induces invagination and 
stabilization of the budding coated pit  [136]. Indeed, endophilin, described below, induces by 
lipid-modifying activity - lysophosphatidic acid acyl transferase (LPAAT) activity, inward 
curvature of the plasma membrane. Any perturbation in this step stops these mechanisms, 
impairing and blocking CME and subsequently the neurotransmitter release [61, 144, 154].
 In the fourth step, vesicle fission is occurring. Clathrin-coated vesicle budding 
depends, mainly, on the mechanochemical GTPase, dynamin, but other proteins seem to be 
involved such as again endophilin, sorting nexin 9 (SNX9) and amphiphysin which have SRC 
homology 3 (SH3) domains that bind the Pro-rich domain of dynamin [154]. These proteins 
cause impairments in neck invagination, essential for dissociation of CCV. Despite endophilin 
and amphiphysin actions, downstream and upstream of vesicle fission, these proteins have 
been suggested to help  the large GTPase dynamin to form a helical collar around the neck of 
an invaginating CCV, where it may regulate, pinch or pop the vesicle from the parent 
membrane [61, 144, 154]. It is shown that GTP hydrolysis is coupled to vesicle scission and 
that on GTP hydrolysis dynamin spirals undergo length-wise extension, which drives the 
vesicle away from the membrane causing lipid fission [154]. In fact, inhibition of dynamin 
reveals a approach to study the endocytosis. An inhibitor available is the dynasore. Dynasore 
interferes in vitro with the GTPase activity of dynamin1, dynamin2, and Drp1, the 
mitochondrial dynamin, but not of other small GTPases. Dynasore acts as a potent  inhibitor of 
endocytic pathways known to depend on dynamin by rapidly blocking coated vesicle 
formation within seconds of dynasore addition. Two types of coated pit intermediates 
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accumulate during dynasore treatment, U-shaped, half formed pits and O-shaped, fully 
formed pits, captured while pinching off [160, 161].
 In the fifth and final step, CCVs must be uncoated, in a process called Uncoating and 
Clathrin component recycling [154]. The clathrin coat is disassembled from its lattice 
arrangement back to triskelia by the ATPase heat  shock cognate (HSC70), the clathrin-
associated protein auxilin or cyclin G-associated kinase (GAK) [154]. Auxilin or GAK is 
recruited after clathrin-coated vesicle budding by  binding to the terminal domains and 
“ankles” of clathrin triskelia. There auxilin/GAK recruits HSC70 to initiate the uncoating 
reaction. To facilitate and accelerate, endophilin and AP2 are detached from plasma 
membrane and help on recruitment of synaptojanin and auxilin, respectively  [154]. Therefore, 
the disruption of HSC70, synaptojanin, auxilin interaction and recruitment of endophilin and 
AP2 leads to impairments in neurotransmission by decreased SV and increased CCVs [61, 
144, 154].
Figure 11. A) Clathrin-coated vesicle formation. Nucleation: FCHO proteins bind PIP2-rich zones of the plasma 
membrane and recruit EPS15–EPS15R and others proteins to initiate clathrin-coated pit formation by recruiting 
AP2. Cargo selection: AP2 recruits several classes of receptors directly through its µ subunit and σ subunit. 
Cargo-specific adaptors (for example, stonin, HRB and Numb) bind to AP2 appendage domains and recruit 
specific receptors to the AP2 hub. Coat assembly: clathrin triskelia are recruited by the AP2 hub and polymerize 
in hexagons and pentagons to form the clathrin coat around the nascent pit. Scission: the GTPase dynamin is 
recruited at the neck of the forming vesicle by BAR domain-containing proteins, where it self-polymerizes and, 
upon GTP hydrolysis,  induces membrane scission. Uncoating: auxilin or GAK recruits the ATPase HSC70 to 
disassemble the clathrin coat and produce an endocytic vesicle containing the cargo molecules. Synaptojanin 
probably facilitates this by releasing adaptor proteins from the vesicle membrane through its PtdIns lipid 
phosphatase activity. The components of the clathrin machinery are then free for another round of clathrin-
coated vesicle formation. B) The clathrin network. The protein–protein interactions underlying the different 
stages of vesicle progression are shown.  Major hubs are obvious because of their central location in the network 
and the large number of interacting molecules. They are essential for pathway progression and are denoted by 
the central colored circles. Possible pathways of progression between hubs are shown with thicker lines [154].
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 Subsequently, the SVs fuse with the early  endosomes to generate new vesicles or are 
conducted to active zone (recycling vesicles), for uptake of neurotransmitters by 
neurotransmitter transporter with help  of vacuolar ATPase control present in SV membranes. 
The fusion with early endosomes is mediated by ras-like small G-proteins, such as Rab5b 
protein, that control trafficking, exocytosis, endocytosis and endosome fusion [39, 61, 80, 144].
 In cell, the active traffic of proteins, as in CME, is very common and the Bin/
Amphiphysin/Rvs (BAR) domain proteins constitute an important heterogeneous superfamily 
of cytoplasmic proteins with a strong commitment to membrane traffic [144, 162]. The best 
characterized BAR domain proteins are endophilins (fig 12) that are involved in SV retrieval, 
mitochondrial network dynamics, receptor Tyr kinase signaling, apoptosis and autophagy. 
There are five endophilin protein types, endophilin A1 (SH3GL2), A2 (SH3GL1), A3 
(SH3GL3), B1 (SH3GLB1) and B2(SH3GLB2). Endophilin A1 is localized in the brain (pre-
synaptic terminals) while endophilin A2, B1 and B2 are expressed in all tissues and the 
endophilin A3 is expressed in testes and in brain [144, 162].
Figure 12. Diagram of endophilin binding to membranes. The BAR domain is responsible for membrane 
binding dimerization and curvature sensing. An amphipathic helix and the N terminus inserts into the membrane 
like a wedge helping to drive positive membrane curvature [163].
 All these endophilins contain, in addition to N-terminal BAR domain, a C-terminal 
SH3 domain. BAR domains are involved with dimerization domains and are able to induce 
and stabilize membrane curvature by formation a crescent-shaped dimer, with each monomer 
made up three kinked, antiparallel, α-helices. SH3 domains are protein-recognition modules 
that adopt the β-barrel core typical of SH3 domains with a hydrophobic groove 
accommodating proline-rich peptide sequences present  in binding partners [162]. Indeed, the 
SH3 domain binds proline-rich domain (PRD)-containing proteins such as synaptojanin, 
dynamin, and ataxin-2, important  proteins to CME[162]. Recently, a study of Milosevic et al., 
(2011) [164] proves that endophilin, a membrane-binding protein with curvature-generating 
and -sensing properties also binds the GTPase dynamin and the phosphoinositide phosphatase 
39
synaptojanin and is thought to coordinate constriction of coated pits with membrane fission 
(via dynamin) and subsequent uncoating (via synaptojanin). They used the knockout of the 3 
mouse endophilins (endophilin A1, A2, A3) to demonstrate that  this lack results in the 
accumulation of clathrin-coated vesicles, but not of clathrin-coated pits at  synapses. This can 
be explain by absence of synaptojanin, an important  protein to promote the uncoating [164]. 
In fact, the absence of endophilin impairs but does not abolish synaptic transmission and 
results in perinatal lethality, whereas partial endophilin absence causes severe neurological 
defects, including epilepsy and neurodegeneration. This paper suggests a model in which 
endophilin As have two main roles: membrane curvature and uncoating CCVs [164, 165].
 As described above, PD-linked mutations in Parkin protein can disrupt SV endocytosis 
[79]. Indeed the same happens with LRRK2 [13, 80, 166]. LRRK2 and its mutants interact 
with domains of endocytic proteins modulating the SV endocytosis process [13, 80, 166]. In 
2008 and 2011, studies showed that alteration of LRRK2 levels in the presynaptic terminal 
impairs the normal synaptic activity by reducing endocytosis [13, 80, 166]. In Shin et al., 
(2008) a reduced rate of vesicle recycling upon LRRK2 overexpression was found and this 
was shown to be mediated by interaction with Rab5b protein, a ras-like small G-protein that 
regulates endocytic vesicular transport from plasma membrane to early endosomes [80]. In 
Piccoli et al., (2011) study, LRRK2 is implicated in the control of vesicle dynamics [13]. 
LRRK2-silenced neurons have unusual high numbers of active synapses under resting 
conditions and when cells are depolarized with potassium chloride (KCl) which increases 
vesicle release of the recycling pool, no additional increase in synaptotagmin staining was 
found in these cells, suggesting that LRRK2 is necessary  to control endocytosis [13]. The 
same observation in RRP was obtained with hypertonic solution, sucrose, solution that is 
thought to stimulate the release of the entire RRP in neuron in culture, thereby  allowing the 
estimation of the RRP itself [13].
 In addition to these studies, LRRK2 also has been associated to other crucial proteins/
complex for SV endocytosis, such as α-actin, a component of cytoskeleton, AP-1, AP-2, 
AP180 protein, SV2, vacuolar ATPase, dynamin, endophilin and clathrin, suggesting that 
LRRK2 may influence endocytosis of SV and neurotransmission by interaction with these or 
other proteins [13].
 In fact, a recent manuscript under review (Neuron) from the host lab describes that 
endophilin A is a direct substrate of LRRK2. In this study, we found that loss of Drosophila 
melanogaster endophilin A rescues synaptic endocytosis deficits in LRRK mutants, 
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suggesting that Endophilin A dominantly  impairs vesicle recycling in the absence of LRRK, 
the LRRK2 variant in Drosophila melanogaster. They also found that the LRRK 
phosphorylates Endophilin A at  Ser 75 in the BAR domain, a domain important in the 
initiation of the membrane curvature in the first  stage of CME. These results prove that 
LRRK2 mediated endophilin A phosphorylation is required to the normal function of 
endocytosis. But, when the phosphorylation is too strong (LRRK clinical mutant) there is a 
impairment on synaptic vesicles endocytosis as well, suggesting that LRRK is part of an 
endophilin A phosphorylation cycle that regulates synaptic vesicle formation and predicts that 
both increased and decreased LRRK/LRRK2 kinase activity may have a deleterious effect in 
synaptic vesicle endocytosis. Therefore it is thought that this (de)phosphorylation alters the 
Endophilin A function (Matta et al., 2012-manuscript accepted).
 They  further showed that when Endophilin A is phosphorylated, it is removed from the 
plasma membrane, blocking the recruitment of some core components, essentials to 
membrane curvature initiation, stopping the CME in the initial stage. In fact in flies, mutant 
G2019S LRRK2 exhibits selective loss of DA neurons, locomotor dysfunction and early 
mortality which is in according with WT LRRK2 (Bacterial artificial chromosome -BAC) 
transgenic mice, where striatal DA transmission and motor performance is enhanced, while 
similar expression of G2019S mutants decreased striatal DA content  as its release and uptake 
[82, 167]. Furthermore, the R1441 (R1441C/G/H) mice show abnormal activity-dependent 
DA neurotransmission, including impairment in stimulation-induced locomotor activity and 
catecholamine release, as well as dopamine D2 receptor-mediated functions, leading to 
degeneration of nigrostriatal projections [82, 167].
 In flies, absence of LRRK, or in the presence of LRRK kinase inhibitors also cause an 
impairment in synaptic vesicles endocytosis because it is thought that the endophilin A 
phosphorylation is required to facilitate recruitment of HSC70, auxilin and synaptojanin, 
important proteins to uncoating reaction. These findings suggested that LRRK2 is essential to 
proposed Endophilin cycle. 
 In figure 13 is represented the possible normal/pathogenic of LRRK2 functions.
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Figure13. Normal and pathogenic functions of LRRK2. LRRK2 has been implicated in regulating the 
microtubule network, actin cytoskeleton, neurite outgrowth, autophagy-lysosomal pathway,  apoptosis, 
mitochondrial morphology and activity, vesicular trafficking (ie, synaptic vesicle exocytosis/endocytosis), 
dopaminergic (DA) neurotransmission, protein translation, and degradation pathways, which could potentially 
underlie neuronal damage. The potential functional interaction of LRRK2 with α-synuclein and tau as well as the 
molecular mechanisms through which disease-associated mutations lead to neurodegeneration.
 1.2.7. LRRK2 Rodent Models
 1.2.7.1. LRRK2 knockout (KO) mice
 The first LRRK2 KO mice was published in 2007, by Biskup  and his coworkers [124, 
157]. LRRK2 KO mice are viable and have no major neuropathological abnormalities or 
motor dysfunction. No loss of DAergic neurons was observed even at 24 months of age 
suggesting that expression of LRRK2 for neuronal survival and to early embryonic 
development is not essential [39, 157]. These features were confirmed by a study that shows 
no significant difference in the susceptibility of LRRK2 KO and WT mice to MPTP. This fact 
could be explained by compensation mechanisms by LRRK1 since LRRK1 shares high 
homology  with LRRK2 and is expressed in the brains (fig.14). In addition, this observation is 
supportive with the gain-of-function hypothesis of LRRK2 mutants. Nevertheless, the LRRK2 
KO mice have some complications in the kidneys [39, 157]. The kidneys of these mice 
accumulate and aggregate α-synuclein, suggest some defects in autophagy, apoptotic cell 
death, oxidative damage and inflammation response [39, 157].
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Figure 14. Schematic of LRRK1 and LRRK2 domain structures: ARM = armadillo, ANK = ankyrin, LRR = 
leucine-rich repeat, ROC = Ras of complex, COR = C terminus of ROC [97].
 
 1.2.7.2. Bacterial artificial chromosome (BAC) transgenic mice of LRRK2
 The use of BAC transgenic mice was initially described in 1997 by Antoch and his 
coworkers [159, 162]. It is a milestone in the past decade because this methodology 
potentiates gene functions studies in vivo, mainly  in CNS. The application of BAC 
transgenics is advantageous over conventional transgenics for studying LRRK2. The 
application of BAC transgenic is advantageous over conventional transgenics for studying 
LRRK2. The main reasons are: generation of LRRK2 BAC transgenic mice does not involve 
the synthesis of full-length LRRK2 complementary DNA (cDNA), which is a > 7 kb 
nucleotide and technically difficult to manipulate as a result of the large size; the entire 
genomic sequence of mouse or human LRRK2 is approximately 180 kb, which is the average 
length of BAC clones that are readily  available in public domains; and LRRK2 BAC 
transgenes with introduced PD mutations are suitable for modeling the LRRK2-mediated 
pathological process as a result of the dominant disease transmission for LRRK2 mutations 
[124, 157].
 BAC transgenic mice have been developed for LRRK2 WT, LRRK2 R1441C/G, 
LRRK2 G2019S and display some hallmarks of neurodegeneration, demonstrated by 
measuring the dopamine content after pharmacologically blocking the dopamine uptake [39, 
157, 162]. The LRRK2 protein expressed in transgenic mice, normally, shares 86% homology 
with the human protein and this expression is broadly distributed in many regions, including 
cortical cortex, hippocampus, striatum, amygdala, cerebellum and OB, as well as in ventral 
tegmental area (VTA) and SN [39, 157].
 The BAC transgenic mice overexpressing the human LRRK2 R1441C/G mutant 
develop typical motor phenotype, beginning with reduced mobility that  was reminiscent of 
hypokinesia in PD [39, 157, 162]. By 10–12 months of age, the hypokinesia in most 
LRRK2R1441G mice had progressed to a visually  apparent immobility, reminiscent of akinesia 
in late PD [162]. These symptoms are reversed by  use of L-DOPA and DA receptor agonists, 
recapitulating the progressive motor deficits and responsiveness to L-DOPA that are 
characteristic of human PD [162]. However, immunohistochemistry for TH in 9–10-month-
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old LRRK2R1441G mice revealed that DAergic neurons in the SNpc and VTA were normal in 
number and anatomical organization but in striatum and piriform cortex, two areas that were 
enriched in DAergic projections, TH–positive axons appeared to be beaded and fragmented 
and exhibited spheroids and dystrophic neurites [162].
 LRRK2R1441C BAC mice and also LRRK2G2019S BAC mice show reduced DA release 
in striatal system in the absence of neuropathology, suggesting that LRRK2 mutants have a 
pathogenic role in this system [39, 157, 162]. In fact, impairment of endocytosis can be 
involved in this reduced DA release as this would compromise the “reconstruction” of SV, 
recycling of plasma membrane proteins of SV and dynamics of plasma membrane [13, 80].
 
 1.2.7.3. Double transgenic mice
 There is clear evidence that LRRK2 and α-synuclein are associated in PD 
pathophysiology [166]. Therefore a double transgenic mice was generated in 2009 expressing 
an inducible PD-related A53T α-synuclein mutant combined with the G2019S LRRK2 
mutant. Interestingly synergistic toxicity to neurons was observed with exacerbated 
progression of α-synuclein-mediated neuropathology [166].
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2. Main objectives of this study
 As described above, PD is the second most common disease, and despite nearly 200 
years since the first description of this disease, a definitive understanding of disease 
pathogenesis and a preventative therapeutic approach is still missing. So gaining insight into 
the pathogenesis and development of an effective disease modifying therapy  are two of the 
major objectives of the host lab. So far, it is known that PD is a neurogenerative disorder 
characterized by DAergic neuron loss and presence of LBs. Nevertheless, the mechanisms 
and pathways that lead to these specific loss and presence of LB remain unknown [2, 23].
The discovery  of gene-linked PD has provided an opportunity to investigate the PD 
pathogenesis. One of this genes/protein, called LRRK2, is a cause of autosomal dominant PD 
and involved in sporadic PD and hence is a good target for investigation. The multi-domain 
structure of LRRK2, with both enzymatic (kinase and GTPase) and interaction domains, 
makes that there are many  layers of regulation controlling the functional outputs of this 
protein. In fact, LRRK2 has been implicated in a wide variety of physiologic function such as 
neuronal survival and cytoskeleton rearrangement, mitochondrial dysfunction, protein 
homeostasis, autophagy, apoptosis, in immune system and in neurotransmission and synaptic 
vesicle endocytosis [78]. An involvement of LRRK2 in the pathogenesis of PD, notably in 
synaptic vesicle endocytosis was discovered in the host lab just before the beginning of this 
study (Matta et al., 2012 - manuscript accepted). These initial findings were however made in 
Drosophila melanogaster. To study  the functional conservation of the role of LRRK2 in 
synaptic vesicle endocytosis in the mammalian neuronal system, to evaluate the LRRK2 
kinase dependency of this phenomenon and to confirm the functional conservation of 
mammalian endophilin in this pathway  the study presented in this thesis was performed.
The working hypothesis is that in analogy with Drosophila melanogaster LRRK, 
mammalian LRRK2 regulates synaptic vesicle endocytosis by acting as a switch via 
phosphorylation of a variant of endophilin. This phosphorylation regulates the subcellular 
localization of endophilin affecting the SV endocytosis with non-phosphorylated and 
phosphorylated endophilin respectively competent and incompetent to interact with the 
membrane of the synaptic vesicle
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3. Material and Methods
 3.1. Mediums and Solutions
Cell Culture
• Hank’s balanced salt sodium solution1  (HBSS) [without Ca2+ and Mg2+] and HEPES2 
solution (HBSS/HEPES) – 3.5 ml of HEPES 1M, 5 ml of Penicillin-Streptomycin3, fill 
up to 500 ml with HBSS filter through a 0.22µm filter4 and stored at 4°C;
• MEM-Horse medium (plating medium) - 50 ml Horse serum (heat-inactivated)5, 15 
ml of 20% glucose6 (glucose was dissolved in milli-Q water, filter through a 0.22µm 
filter store at 4°C), fill up to 500 ml with MEM 1x [+ Earle’s, + L-Glutamine]7, filter 
through a 0.22µm filter and stored at 4°C;
• B27 L-glutamine (sustaining medium) - 485 ml Neurobasal medium, 10 ml B27 
supplement8, 5 ml L-glutamine9, filter through a 0.22µm filter and stored at 4°C.
Electrophysiological solutions
• Internal solution (mM): K-gluconate10  146; HEPES 17.80; Mg-ATP11 4.00; Na2-ATP12 
0.30; EGTA13 1.00 and Phosphocreatine14 12.00, pH 7.3 adjusted with KOH (2M) and 
osmolarity 300 mOSmol kg-1, adapted from Rost et al., 2010 [168].
• Bath Solution - Extracellular saline solution (mM): NaCl15  140.00; KCl16  2.40; 
HEPES17  10.00; D-Glucose-H2O18  10.00; CaCl219  2.50 and MgCl220  1.30, pH 7.3 
adjusted with KOH (2M) and osmolarity  300 mOsmol kg-1, adapted from Rost et al., 
2010 [168].
• Sucrose solution contained the same composition as bath solution. Sucrose21 was added 
to a final concentration of 50 mM (350 mOsmol kg-1, pH 7.3).
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1 Product number: 14175 – Company: Invitrogen/Gibco
2 Product number: 15630-122 (20 x 100 ml) – Company: Invitrogen/Gibco
3 Product number : 15140 – Company: Invitrogen/Gibco
4 Product number Stericup & Steritop system Express PLUS (0.22µm) Cat. N° SCGPU05RE – Company: Millipore.
5 Product number: 26050088 – Company: Invitrogen – Quantity: 500 ml
6 Product number: 104074.1000 – Company: Merck – Quantity: 1kg
7 Product number: 31095-052 (10 x 500 ml) – Company: Invitrogen/Gibco
8 Product number: 17504-044 (10ml) – Company: Invitrogen/Gibco
9 Product number: 25030 – Company: Invitrogen/Gibco
10 Product number: D-Gluconic Acid (2,3,4,5, 6-Pentahydroxycaproic Acid) Potassium Salt G4500 - Company: Sigma
11 Product number: Adenosine 5-Triphosphate magnesium salt, from bacterial source A9187-500MG - Company: Sigma
12 Product number: Adenosine 5-Triphosphate A7699 - Company: Sigma
13 Product number: Ethylene glycol-bis (2-aminoethyl-ether) - N,N,N’,N’-tetracetic acid E4378-100G - Company: Sigma
14 Product number: Phosphocreatine disodium salt hydarte enzymatic, approx. 98% P7936-5G - Company: Simga
15 Product number: 27810295 - Company: BDH Prolabo/VWR - Quantity: 1kg 
16 Product number: 1049361000 - Company: Merck - Quantity: 1kg
17 Product number: H75223-250G - Company Sigma
18 Product number: D(+)-Glucose monohydrate 1083421000 - Company: Merck - Quantity: 1kg
19 Product number: 21107-1L – Company: Sigma
20 Product number: M8266-1KG – Company: Sigma
21 Product number: S0389-500G – Company: Sigma
 3.2. Animals
All experiments were performed with embryos WT (B6.Cg-Tg(Lrrk2)6Yue/J), KO 
LRRK2 (B6.129X1(FVB)-Lrrk2tm1.1Cai/J) C57BL/6J mice 17-19 days (E17-E9 days). The 
animals were housed in an animal facility that is fully compliant with the European policy on 
the use of Laboratory Animals. Experimental protocol was approved by the Institutional 
Review Committee of Janssen Pharmaceutica (Beerse, Belgium) and meet the European and 
Belgian guidelines on animal experimentation.
 The animals (26, 15 WT and 11 LRRK2 KO mice) were maintained on a 12 hours 
light/dark cycle and were provided food with and water ad libitum. Care was taken to reduce 
the number of used animals.
 3.3. Preparation of Petri dishes/cover glasses
 The coating process takes 2 days. To prepare the Petri dishes/cover glasses coating 
solution, 5 ml of milli-Q water was added to 5 mg poly-D-lysine 22 (PDL) to obtain a final 
concentration of 1 mg/ml (stock solution, stored at –20 ºC). The PDL solution was mixed and 
2 ml aliquots with a concentration of 0.1 mg/ml (work solution) were stored at 4 ºC.
 Cover glasses23 were cleaned for 3 hours with nitric acid (HNO3) and washed 3 times 
with milli-Q water (30 min) before the coating process. Cover glasses were pre-sterilized in 
70% ethanol for 30 minutes and sterilized by heat (180 ºC, 4h).
 The coating process was done by addition of 200 µl of work PDL solution in the center 
of 3.5 cm Petri dishes24 or 100 µl on cover glasses. Petri dishes/cover glasses were incubated 
at room temperature overnight and next day the solution was aspirated. Petri dishes/cover 
glasses were washed 2 times (20 min) with milli-Q water and left in a laminar flow hood to 
dry. 
 
 3.4. Cell culture
 One day before dissection, the plating and sustaining medium were added to tissue 
culture flasks25 (T250) and placed in a humidified incubator at 37 ºC and 5% CO2.
 On the day  of dissection the HBSS/HEPES solution was pre-warmed to 37 ºC on a 
heating plate. 10 cm Petri dishes26  (10 ml) and in 3.5 cm Petri dishes27  (1ml) were used to 
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22 Product number: P6407-5MG - Company: Sigma 
23 Product number: A10143263NR1 – Company: Thermo Scientific
24 Product number: 150318 - Company: DishesNuclon™/Thermo Scientific
25 Product number: Falcon 353003 tissue culture dishes, 100 x 20 mm – Company: Becton Dickinson Labware
26 Product number: Falcon 353003 tissue culture dishes, 100 x 20 mm – Company: Becton Dickinson Labware
27 Product number: Falcon 353001 tissue culture dishes, 35 x 10 mm – Company: Becton Dickinson Labware
collect the embryo’s heads and embryonic brains, respectively. One of the 3.5 cm Petri dishes 
was filled with 2.5 ml HBSS/HEPES to collect hippocampi. A 15 ml centrifuge tube28  with 
4.5 ml HBSS/HEPES was placed in a warm water bath (37 ºC). The trypsin29  solution 0.5% 
(10X) [with EDTA] was retrieved from the fridge and left in laminar flow hood.
 Large forceps and scissors were sterilized with 70% ethanol. The pregnant mice (day 
E17-E19) were sacrificed by cervical dislocation. A large incision was made in the skin of 
abdomen on the midline starting from the pelvis up to the thorax. The skin was separated 
from muscle tissue, exposing the surface of the abdomen. A large area was opened to reach 
the embryos. The uterus was placed in a 10 cm Petri dish and covered with a lid.
 In laminar flow hood, the embryos were removed from the uterus and decapitated. The 
heads were transferred to the 10 cm Petri dish containing pre-warmed HBSS/HEPES. The 
forehead was perforated with curved forceps to keep the head stable. The skull was removed 
by perforation above the eyes, using a lateral movement, one hemisphere at time. The brains 
were removed out the skull and placed with the ventral side facing up  into 3.5 cm dishes 
containing HBSS/HEPES. When all brains were collected, the hippocampi were isolated 
under a dissection microscope.
 The 2 hemispheres were removed from the diencephalon and the brain stem. With the 
internal side hemispheres facing up, the meninges was removed. Then the hippocampus was 
collected and transferred into to 3.5 cm dish with 2.5 ml pre-warmed HBSS/HEPES.
 After hippocampi were dissected, they were transferred into a 15 ml centrifuge tube. 
The HBSS/HEPES solution was removed and 500 µl of trypsin 0.5% (10 xs) solution was 
added to the 15 ml centrifuge tube with 4.5 ml HBSS/HEPES. This solution was added to 
hippocampi and incubated for 10-15 minutes in the warm water bath. The solution was 
removed and hippocampi were washed 2 times with 3-5 ml plating medium.
 After enzymatic dissociation, tissue was resuspended in 3 ml of plating medium. The 
mechanical dissociation was done by  first pipetting 30 times using a sterile glass Pasteur 
pipette30  with standard tip  diameter and then by pipetting 30 times using a Pasteur pipette 
with reduced fire-polished tip  diameter. The cells were centrifuged at 1000 rpm for 5 minutes, 
resuspended in 2 ml of plating medium and then counted using the Vi-Cell automatic counter.
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28 Product number: Falcon Blue Max Jr. 15 ml polypropylene conical tube, 17 x 120 mm 352097 – Company: Becton Dickinson Labware
29 Product number: 15400 – Company: Invitrogen/Gibco (without phenol red)
30 Product number: Disposable glass Pasteur pipettes, 230 mm, pre-plugged D812 – Company: Volac
 The cells were plated at a density 50.000 cells/ml in Petri dishes/cover glasses coated 
with PDL. Cells were left overnight in the incubator at  37 ºC and 5% CO2. Then, plating 
medium was removed and replaced with sustaining medium.
 Cells were used for electrophysiological experiments 7-12 days after plating.
 3.5. Electrophysiology
 Petri dishes/cover glasses containing the neuronal network were placed under a Carl 
Zeiss Axioskop 2FS upright microscope (Jena, Germany). Sustaining medium was changed to 
bath solution and all experiments were performed at room temperature (18-22 ºC)
 Pyramidal neurons were voltage clamped at  a holding potential of -70 mV with 
pipettes for patch-clamp recording (electrodes) under HEKA software. Recordings were 
digitized and stored on the computer hard drive (sample frequency 10 kHz, filter frequency 5 
kHz). Electrodes31 (thick-walled borosilicate glass capillaries with outer diameter 1.5 mm and 
inner diameter 0.86 mm) were pulled with a P97 Flaming/Brown Micropipette Puller (Sutter 
Instruments). The micropipette tip  was heated with a micro forge to produce a smooth 
surface. The diameter and the resistance of these polished tips were ≈ 1µm and 3-5 MΩ, 
respectively. The electrodes were filled with internal solution.
 Signals/events were recorded during 10 seconds with an EPC10 USB Patch Clamp 
Amplifier (HEKA) and analyzed using a PC and Igor Pro 6.2.2.2 software (WaveMetrics, 
Inc.). The GABA-mediated responses were avoided by voltage clamping neurons at -70 mV. 
The use of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX)32, an 
AMPA receptor antagonist, at 10 µM showed no sEPSC in control neither in sucrose, which 
prove that we were recording the Glutamatergic-mediated responses.
 After recording 10s in bath solution, this solution was replaced to a hypertonic sucrose 
solution (50 mM  sucrose, 350 mOsmol kg-1) by perfusion. After 2 min perfusion, a new 
recording was made and same parameters were measured.
 3.6. Drugs
 Dynasore33  was stored frozen at a concentration of 20 mM (in DMSO34) in 200 µl 
aliquots and diluted to a final concentration of 40 µM (0.2% DMSO) in bath solution and 
sucrose solution. After placing the dish under the microscope the sustaining medium was 
50
31 Product number: 300057 - Company: Harvard Apparatus
32 Product number: N171-5MG – Company: Sigma
33 Product number: 324410 – Company: Calbiochem
34 Product number: 1.02952.1000 – Company: Merck
changed, to bath solution containing the compound. After 5 min, a cell was selected, patched 
and control recording was made. By perfusion the solution was replaced to sucrose solution 
plus compound in the same concentration for 2.5 min and the recording was repeated.
 LRRK2-IN-135  was stored at -4 ºC at a concentration of 10 mM (in DMSO) and 
diluted to a final concentration of 0.1 µM, 0.3 µM or 1 µM  (0.2% DMSO). Cells were pre-
treatment for 1 hour with compound. After placing the dish under the microscope the medium 
with the compound was changed, to bath solution containing the compound in the same 
concentration. A cell was selected, patched and control recording was made. By  perfusion the 
solution was replaced to sucrose solution plus compound in the same concentration for 2.5 
min and recording was repeated.
 To control, the cells were pre-treatment for 1 hour with DMSO 0.2% dissolved in 
sustaining medium.
 3.7. Data Analysis
Using Igor Pro 6.2.2.2 software, raw data traces obtained with HEKA software were 
transferred to an Excel template, which detects the sEPSC events based on time and threshold 
of the event. Events that exceed 5 ms in duration and have amplitude less than -10 pA were 
not considered as a sEPSC. 
Graphs are generated with GraphPad Prism 4.02 and values are represented as mean ± 
Standard Error of the Mean (SEM) from n cells/experiments. Statistical significance was 
assessed by a two-tailed Student’s t test for the experimental versus control condition, one-
way ANOVA followed by Dunnett's Multiple Comparison Test or two-way ANOVA. A p 
value of 0.05 or less was considered for significant differences.
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35  Product number: 438193-5MG: 5,11-Dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-6H-
pyrimido[4,5 b][1,4]benzodiazepin-6-one, Company: Merck Millipore Home
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4. Results
LRRK2 is widely expressed in neurons throughout the CNS, including cortex, 
hippocampus, striatum, and other brain areas [78, 111, 113].
Recent publications and findings in the host lab propose an involvement of LRRK2 in 
neurotransmitter release [70] and a function in the pre-synaptic protein network, coordinating 
both the storage and the mobilization of SVs [13] by interaction with Rab5 [80] and 
endophilin A1 (Matta et. al., 2012-manuscript accepted). In this study, we studied the 
functional conservation of the role of LRRK2 in synaptic vesicle endocytosis in the 
mammalian neuronal system and the LRRK2 kinase dependency  of this phenomenon (Matta 
et. al., 2012-manuscript accepted).
LRRK2 absence causes impairments in pre-synaptic function 
To confirm a role of LRRK2 in modulation of synaptic function in mammalian 
neurons, we measured the number, frequency  and amplitude of sEPSCs, via whole-cell patch 
clamp in hippocampal neurons derived from WT and LRRK2 KO mice. As LRRK2 
expression is only detected in the rodent brain from embryonic day 16 to 17 (E16-E17) [78], 
WT and LRRK2 KO mice were used between embryonic day 17 to 19 (E17-E19 days) 
between 7-12 days in culture (fig. 15).
    
    
Figure 15.  Hippocampal cells in 7 days culture. A, B; WT hippocampal cells, 7 days in culture, with 
magnifications of 40x and 100x,  respectively.   C, D; LRRK2 KO hippocampal cells, 7 days in culture, with 
magnifications of 40x and 100x, respectively.
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 To make sure that we were recording the sEPSC and not sIPSC, during the 
experiments, we performed some recordings in WT and LRRK2 KO hippocampal cells in 
control and sucrose conditions (n=7) in the presence of NBQX, an AMPA receptor antagonist 
at 10 µM and compared those to the currents measured in the absence of NBQX. NBQX 
impaired the AMPA- and NMDA-mediated currents (Glutamatatergic-mediated responses) 
recording in post-synaptic cell by blocking the AMPA receptor. This indicates that sEPSC are 
the result of binding of glutamate to AMPA receptors that are essential to neurotransmission 
(fig. 16)
Figure 16. AMPA receptor antagonist (NBQX) blocks the sEPSC. Representative recordings of WT 
hippocampal cells (9 days in culture) in presence of NBQX in control (A) and sucrose (B), and in absence of 
NBQX in control (E) and sucrose (F). Representative recordings of LRRK2 KO hippocampal cells (9 days in 
culture) in presence of NBQX, control (C) and sucrose (D), and in absence of NBQX in control (G) and sucrose 
(H).
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The sEPSCs, as described above, are the result of the different number of release 
points (synapses) that each cell can form, number of receptors available in post synaptic cells 
and the network of the cell culture. Under basal conditions, the currents measured are similar 
in the two genotypes. In presence of sucrose (50 mM), the number of EPSCs in WT 
hippocampal cells was drastically increased in the presence of sucrose (n=19; control, 47.74 ± 
14.03; sucrose, 100.84 ± 19.62) (fig.17A,B and 17E; ρ<0.05, two-tailed Student’s t test). 
Conversely, in LRRK2 KO hippocampal cells (n=22; control, 32.05 ± 8.07; sucrose, 43.14 ± 
9.76) sucrose treatment failed to induce an increase in the number of sEPSC (fig.17C, D, E). 
Sucrose is thought to stimulate the release of the entire RRP (depletion of total RRP) in the 
neuronal culture, by mechanical stress (independently of Ca2+), producing a parallel depletion 
and refilling of the pool used by action potential-evoked release (recycling pool and reserve 
pool) [169]. Determination of the sucrose/bath ratio showed that the application of sucrose 
promotes a fold-change of 4.07 ± 1.38 in WT (n=19) and 1.69 ± 0.37 in LRRK2 KO 
hippocampal cells (n=22) (fig. 17F, ρ<0.05, two-tailed Student’s t test).
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Figure 17. LRRK2 KO causes impairment in neurotransmitter release.  Single recordings were performed in 
post-synaptic WT or LRRK2 KO cells that receive inputs from the neuronal network. Representative whole-cell 
patch clamp recordings from WT hippocampal cells in control (A) and sucrose (50 mM) (B); Representative 
whole-cell patch clamp recordings from LRRK2 KO hippocampal cells in control (C) and sucrose (50 mM) (D). 
(E) Sucrose significantly increased the number of sEPSC in WT  hippocampal cells (n=19; control, 47.74 ± 
14.03; sucrose, 100.84 ± 19.62) but not in LRRK2 KO hippocampal cells (n=22; control, 32.05 ± 8.07; sucrose, 
43.14 ± 9.76). (F) Sucrose (50 mM) induces a fold change on number of sEPSC in WT and LRRK2 KO 
hippocampal cells of 4.07 ± 1.38 and 1.69 ± 0.37, respectively. (G) Sucrose significantly increased the frequency 
(Hz) in WT hippocampal cells (n=19; control, 26.32 ± 4.27; sucrose, 46.64 ± 6.48) but not in LRRK2 KO 
hippocampal cells (n=22; control, 35.44 ± 4.01; sucrose, 30.00 ± 4.67). (H) Sucrose (50 mM) induces a fold 
change on frequency (Hz) in WT  and LRRK2 KO hippocampal cells of 2.08 ± 0.33 and 0.97 ± 0.18, 
respectively; (I) Sucrose did not affect the peak amplitude in both genotypes (WT: n=19; control, -25.90 ± 2.84; 
sucrose, -25.27 ± 2.47); (KO: n=22; control, -19.44 ± 1.97; sucrose, -18.26 ± 1.37) and (J) the fold change does 
not show a significant difference (WT; n=19; 1.09 ± 0.17) and (KO; n=22; 0.99 ± 0.06). Data are expressed as 
mean ± SEM. # p=0.08, *p<0.05, two-tailed Student’s t test.
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As the number of sEPSC and the efficiency of synaptic transmission depend on the 
availability of post-synaptic receptor and not only the pre-synaptic probability  of release, we 
asked whether LRRK2 might be involved in presynaptic and/or post-synaptic cell. We thus 
looked whether presence and absence of LRRK2 might affect presynaptic mechanisms 
including recycling of the synaptic vesicles. To study this, we analyzed the frequency (Hz) of 
sEPSC (basal and sucrose-stimulated) in neurons from WT and LRRK2 KO mice. As 
expected, the presence of sucrose stimulates the neurotransmitter release and induces a 
significant increase in frequency in WT hippocampal cells (n=19; control, 26.32 ± 4.27; 
sucrose, 46.64 ± 6.48). Nevertheless, in LRRK2 KO hippocampal cells (n=22; control, 35.44 
± 4.01; sucrose, 30.00 ± 4.67) the stimulating effect is absent (fig 17G, *ρ<0.05, two-tailed 
Student’s t test). Data in figure 17G show that in control, the LRRK2 KO neurons shows a 
slightly (not significant) increase in frequency when compared to control in WT hippocampal 
cells. The increase in frequency is dependent on presynaptic machinery proteins and showed a 
normal increase in WT hippocampal cells (2.08 ± 0.33, n=19) but in LRRK2 KO hippocampal 
cells the frequency  remains the same (0.97 ± 0.18, n=22) (fig. 17H, *ρ<0.05, two-tailed 
Student’s t test). As frequency of sEPSC is a valid parameter [149] of pre-synaptic functions, 
these results suggest that presence of LRRK2 is essential in pre-synaptic mechanisms to 
replenish the synaptic vesicles pool to govern high frequency neurotransmission.
As mentioned above, neuronal communication is dependent on both the pre-synaptic 
cell and post-synaptic functions in the neurons. While both pre- and post-synaptic 
mechanisms can determine the peak sEPSC amplitude, conventionally  sEPSC amplitude 
changes are thought to reflect changes in the response of post-synaptic receptors [170, 171]. 
Thus, to evaluate whether LRRK2 affects the post-synaptic mechanism, we evaluate the peak 
amplitude in the same recordings. For both WT and LRRK2 KO hippocampal cells, there 
were no differences observed between control and sucrose conditions (WT: n=19; control, 
-25.90 ± 2.84; sucrose, -25.27 ± 2.47); (KO: n=22; control, -19.44 ± 1.97; sucrose, -18.26 ± 
1.37) (fig 17I, #ρ=0.08, *ρ<0.05, two-tailed Student’s t test). These results were also further 
quantified by looking at the ratio sucrose/control, where it was confirmed that the peak 
amplitude remain unchanged (WT; n=19; 1.09 ± 0.17; KO; n=22; 0.99 ± 0.06) (fig. 17J). 
Although, the sucrose solution did not affect the peak amplitude in the two genotypes, we can 
observe that peak amplitude is lower in LRRK2 KO hippocampal cells than in WT 
hippocampal. The ρ value is < 0.05 under sucrose-stimulated conditions but in control the ρ 
value is 0.08, which can suggest that in both conditions, LRRK2 KO hippocampal have 
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smaller peak amplitude than WT hippocampal cells. This evidence might be attributed to the 
fact that in LRRK2 KO cells there are less synaptic vesicles to release, even under hypertonic 
solution. These results again suggest a role of LRRK2 in modulating presynaptic vesicle 
release.
Blockade GTPase Dynamin by dynasore mimics the effect of LRRK2 KO
Synaptic transmission between neurons requires the coordinated activity  of numerous 
cellular elements to achieve the sustained communication necessary  for normal nervous 
system function. Given the electrophysiological changes showed in previous results, we asked 
if LRRK2 is involved in endocytosis or exocytosis. We thus treated the cells with dynasore 
(40 µM, 5 min), a cell-permeable, small molecule and noncompetitive inhibitor of dynamin 1, 
2, often used to study the endocytosis (fig.18A-H).
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Figure 18.  Blockade of GTPase dynamin by dynasore mimics the effect of absence of LRRK2. Single 
recordings were performed in post-synaptic WT or LRRK2 KO hippocampal cells that receive inputs from the 
neuronal network. Representative whole-cell patch clamp recordings from WT  hippocampal cells in control (A) 
treated with dynasore (40 µM) (C) and in sucrose (50 mM) (B) treated with dynasore (40 µM) (D). 
Representative whole-cell patch clamp recordings from LRRK2 KO hippocampal cells in control (E) treated 
with dynasore (40 µM) (G) and in sucrose (50 mM) (F) treated with dynasore (40 µM) (H). (I) Sucrose (50 mM) 
significantly increased the number of sEPSC in WT hippocampal cells not treated with dynasore (40 µM) (n=15; 
control, 24.80 ± 6.35; sucrose, 62.73 ± 17.21) but not in LRRK2 KO hippocampal cells (n=12; control, 45.09 ± 
14.00; sucrose, 51.09 ± 12.89). The dynasore (40 µM) increases the number of sEPSC in both genotypes but 
abolish the effect of sucrose in WT hippocampal cells (WT; n=14; control, 119.57 ± 31.76; sucrose, 147.36 ± 
34.02) (KO; n=14; control, 97.56 ± 15.00; sucrose, 139.78 ± 30.78). (J) Sucrose (50 mM) induces a fold change 
on number of sEPSC in WT and LRRK2 KO hippocampal cells no treated with dynasore (40 µM) of 3.77 ± 0.66 
and 1.82 ± 0.40, respectively. The fold change on number of sEPSC in cells treated with dynasore (40 µM) is: 
WT; n=14: 1.72 ± 0.25 and KO; n=14: 1.55 ± 0.23. (K) In hippocampal cells not treated with dynasore (40 µM), 
sucrose significantly increased the frequency (Hz) in WT hippocampal cells (n=15; control, 18.98 ± 4.05; 
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sucrose, 35.37 ± 6.43) but not in LRRK2 KO hippocampal cells (n=12; control, 29.66 ± 4.74; sucrose,  33.10 ± 
5.70). In hippocampal cells treated with dynasore (40 µM), WT  hippocampal cells (n=14; control, 48.30 ± 6.52; 
sucrose, 54.17 ± 5.61) show larger frequencies in two conditions when compared with cells not treated but the 
effect is abolish (KO: n=14; control, 40.60 ± 6.38; sucrose, 46.15 ± 7.66). (L) Sucrose (50 mM) induces a fold 
change on frequency in WT and LRRK2 KO hippocampal cells no treated with dynasore (40 µM) of 2.63 ± 0.47 
and 1.18 ± 0.10, respectively. The fold change on frequency in cells treated with dynasore (40 µM) is: WT; 
n=14: 1.33 ± 0.18 and KO; n=14: 1.11 ± 0.17. (M) Sucrose (50 mM) did not affect the peak amplitude in both 
genotypes not treated with dynasore (40 µM) (WT: n=15; control, -22.69 ± 2.76; sucrose, -26.18 ± 3.68); (KO: 
n=12; control, -20.56 ± 3.24; sucrose, -22.27 ± 4.50) and treated with dynasore (40 µM) (WT: n=14; control, 
-19.13 ± 2.63; sucrose, -20.48 ± 3.19); (KO: n=14; control, -23.62 ± 2.55; sucrose, -22.42 ± 2.50) and  (N) the 
fold change does not show a significant difference (WT not treated; n=15; 1.14 ± 0.05; WT treated; n=14; 1.05 ± 
0.03) and (KO not treated; n=12; 1.15 ± 0.25; KO treated; n=14; 0.96 ± 0.05).  Data are expressed as mean ± 
SEM. *p<0.05 versus WT untreated, two-tailed Student’s t test, #p<0.05 versus WT/KO untreated,  two-tailed 
Student’s t test.
The number of sEPSC in WT hippocampal cells was increased in presence of sucrose 
when the cells were exposed to the DMSO (vehicle) (n=15; control, 24.80 ± 6.35; sucrose, 
62.73 ± 17.21) but the cells exposed to dynasore (40 µM) were unable to induce a significant 
increase (n=14; control, 119.57 ± 31.76; sucrose, 147.36 ± 34.02). As seen before, in LRRK2 
KO hippocampal cells, the sucrose was unable to increase the number of sEPSC in both cells 
treated with DMSO (n=12; control, 45.09 ± 14.00; sucrose, 51.09 ± 12.89 and dynasore (40 
µM) (n=14; control, 97.56 ± 15.00; sucrose, 139.78 ± 30.78) (fig. 18I, #ρ<0.05 versus WT or 
KO not treated, *ρ<0.05, two-tailed Student’s t test). In addition, WT hippocampal cells 
treated with dynasore (WT not treated: n=15; 3.77 ± 0.66; WT treated: n=14: 1.72 ± 0.25) 
show the same ratio that is observed in LRRK2 KO hippocampal cells treated (n=14: 1.55 ± 
0.23) or not treated (n=14: 1.82 ± 0.40) with dynasore (fig 18J, *ρ<0.05, two-tailed Student’s 
t test).
The frequency of the events in WT hippocampal cells was increased by  sucrose (50 
mM) (n=15; control, 18.98 ± 4.05; sucrose, 35.37 ± 6.43) but, as we expected in LRRK2 KO 
hippocampal cells, this effect is abolished (n=12; control, 29.66 ± 4.74; sucrose, 33.10 ± 
5.70). When the cells are treated with dynasore (40 µM), the stimulating effect of sucrose is 
neutralized and the frequency is not significantly different in both genotypes (WT: n=14; 
control, 48.30 ± 6.52; sucrose, 54.17 ± 5.61) (KO: n=14; control, 40.60 ± 6.38; sucrose, 46.15 
± 7.66) (fig. 18K, #ρ<0.05 versus WT or KO not treated, *ρ<0.05, two-tailed Student’s t test). 
From quantification of sucrose/control ratio in the presence and absence of dynasore, it could 
be determined that the frequency  in untreated WT hippocampal cells (n=15; 2.63 ± 0.47) was 
increased while in WT hippocampal cells treated (n=14; 1.33 ± 0.18) with dynasore (40 µM) 
this was not the case. Both LRRK2 KO hippocampal cells treated (n=14: 1.11 ± 0.17) and not 
treated (n=12; 1.18 ± 0.10) with dynasore (40 µM) do not exhibit differences in ratio (fig. 
18L, *ρ<0.05, two-tailed Student’s t test).
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A remarkable observation is the fact that treatment with dynasore increased the 
number of sEPSC detected in both genotypes and the frequency of WT hippocampal cells in 
control and sucrose. It is not clear if these effects are caused by non-specific effects of 
dynasore or if dynamin inhibition leads an adaption of synaptic cycle recruiting, but some 
studies have described a significant increase in spontaneous release and frequency at 
excitatory synapses between cultured cortical neurons [161, 172, 173].
The last  parameter evaluated was the peak amplitude. The peak amplitude in WT and 
LRRK2 KO hippocampal cells in both control and sucrose was not altered with the treatment 
with vehicle (WT: n=15; control, -22.69 ± 2.76; sucrose, -26.18 ± 3.68); (KO: n=12; control, 
-20.56 ± 3.24; sucrose, -22.27 ± 4.50) and dynasore (40 µM) (WT: n=14; control, -19.13 ± 
2.63; sucrose, -20.48 ± 3.19); (KO: n=14; control, -23.62 ± 2.55; sucrose, -22.42 ± 2.50) (fig.
18M). Also no alteration was observed in terms of ratio (WT not treated; n=15; 1.14 ± 0.05; 
WT treated; n=14; 1.05 ± 0.03) and (KO not treated; n=12; 1.15 ± 0.25; KO treated; n=14; 
0.96 ± 0.05) (fig.18N).
Collectively, the experiments shown in figure 18 show that treatment of neurons with 
dynasore mimicked the effect  of LRRK2 absence, suggesting that the observed impairment in 
synaptic function in LRRK2 KO neurons has a strong endocytic component.
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LRRK2 kinase activity is essential to endocytosis of synaptic vesicles
 In accordance with the proposed hypothesis, LRRK2 is part of a complex of 
presynaptic proteins that  modulates synaptic vesicle endocytosis. A recently identified 
mechanism in Drosophila melanogaster involves the vesicle binding of Endophilin A1, which 
is regulated by  phosphorylation at residue 75 in BAR-domain of endophilin (Matta et al., 
2012 – manuscript accepted). If conserved in mammalian neurons, this would mean that the 
effect of LRRK2 on endocytosis depends on kinase activity. To confirm this with functional 
data, we asked if the effects observed in LRRK2 KO neurons can be mimicked in WT 
neurons treated with a LRRK2 kinase inhibitor. Therefore, we did recordings (basal and 
sucrose-stimulated) in the presence of LRRK2-IN-1 (0.2% DMSO) at 0 µM  (n=15), 0.1 µM 
(n=10), 0.3 µM (n=10) and 1 µM (n=10) in WT neurons (fig. 19A-H).
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Figure 19. LRRK2 kinase domain is essential to endocytosis of synaptic vesicles. Single recordings were 
performed in pre-treated (1h) WT  hippocampal cells that receive inputs from the neuronal network in presence 
of LRRK2-IN-1 (0.2% DMSO) at 0 µM, 0.1 µM, 0.3 µM and 1 µM. Representative whole-cell patch clamp 
recordings from WT hippocampal cells (LRRK2-IN-1, 0 µM) in control (A) and in sucrose (50 mM) (B). 
Representative whole-cell patch clamp recordings from WT hippocampal cells (LRRK2-IN-1, 0.1 µM) in 
control (C) and in sucrose (50 mM) (D). Representative whole-cell patch clamp recordings from WT 
hippocampal cells (LRRK2-IN-1, 0.3 µM) in control (E) and in sucrose (50 mM) (F).  Representative whole-cell 
patch clamp recordings from WT hippocampal cells (LRRK2-IN-1, 1 µM) in control (G) and in sucrose (50 
mM) (H). (I) Sucrose (50 mM) significantly increased the number of sEPSC in WT hippocampal cells treated 
with LRRK2-IN-1 at 0 µM (n=15; control, 24.80 ± 6.35; sucrose, 62.73 ± 17.21), 0.1 µM (n=10; control, 22.50 
± 3.11; sucrose, 51.60 ± 11.48), 0.3 µM (n=10; control, 49.60 ± 9.00; sucrose, 104.10 ± 22.00), but not at 1 µM 
(n=10; control, 23.60 ± 4.93; sucrose, 39.2 ± 11.42). (J) Sucrose (50 mM) induces a fold change on number of 
sEPSC in WT hippocampal cells (n=15) no treated with LRRK2-IN-1 of 3.77 ± 0.66. The fold change on 
number of sEPSC in cells treated with LRRK2-IN-1 at 0.1 µM (n=10; 2.34 ± 0.32), 0.3 µM (n=10; 2.08 ± 0.20) 
and 1 µM (n=10; 1.84 ± 0.30) are significantly decreased. (K) In WT hippocampal cells treated with LRRK2-
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IN-1 at 0 µM (n=15; control, 18.98 ± 4.05; sucrose, 35.37 ± 6.43), 0.1 µM (n=10; control,  20.54 ± 2.48; sucrose, 
42.47 ± 6.53) and 0.3 µM (n=10; control, 20.90 ± 3.65; sucrose, 37.24 ± 6.74) sucrose significantly increased the 
frequency (Hz) but not at 1 µM (n=10; control, 12.19 ± 3.02; sucrose, 15.21 ± 4.31). (L) The effect of sucrose 
(50 mM) in presence of LRRK2-IN-1 at 1 µM (n=10; 1.31 ± 0.17) is significant decreased but in LRRK2-IN-1 at 
0 µM (n=15; 2.63 ± 0.47), at 0.1 µM (n=15; 2.11 ± 0.27) and 0.3 µM (n=10; 1.89 ± 0.13) the effect remains. (M) 
Sucrose (50 mM) and LRRK2-IN-1 at different concentrations did not affect the peak amplitude (0 µM: n=15; 
control, -22.69 ± 2.76; sucrose, -26.18 ± 3.68); (0.1 µM: n=10; control,  -20.10 ± 1.61; sucrose, -24.10 ± 3.78); 
(0.3 µM: n=10; control, -17.27 ± 0.77; sucrose, -19.16 ± 0.99); (1 µM: n=10; control, -18.66 ± 1.93; sucrose, 
-22.27 ± 3.90) and (N) the fold change does not show differences in presence of LRRK2-IN-1 at 0 µM; (n=15; 
1.14 ± 0.05), 0.1 µM (n=10; 1.19 ± 0.14), 0.3 µM (n=10; 1.12 ± 0.05) and 1 µM (n=10; 1.18 ± 0.13).  Data are 
expressed as mean ± SEM. *p<0.05 versus WT untreated, Student’s t test,  *#p<0.05 versus WT/KO untreated, 
Student’s t test, #p<0.05 versus WT untreated, One-way ANOVA followed by Dunnett's Multiple Comparison 
Test, Two-way ANOVA for dose-dependent in frequency
From the data shown in figure 19 (A, B and I) it is clear that the number of sEPSC is 
increased after perfusion with sucrose in presence LRRK2-IN-1 at 0 µM (n=15; control, 24.80 
± 6.35; sucrose, 62.73 ± 17.21), LRRK2-IN-1 at 0.1 µM (n=10; control, 22.50 ± 3.11; 
sucrose, 51.60 ± 11.48) and LRRK2-IN-1 at  0.3 µM (n=10; control, 49.60 ± 9.00; sucrose, 
104.10 ± 22.00) but in LRRK2-IN-1 at 1 µM   (n=10; control, 23.60 ± 4.93; sucrose, 39.2 ± 
11.42) there is no significant increase (fig.19I, *ρ<0.05, two-tailed Student’s t test). Also here 
this effect was quantified and in the absence of LRRK2-IN-1 (0 µM) sucrose can trigger a 
larger increase (n=15; 3.77 ± 0.66) when compared with cells treated with compound at 
different concentrations (LRRK2-IN-1 at 0.1 µM (n=10; 2.34 ± 0.32), 0.3 µM  (n=10; 2.08 ± 
0.20) and 1 µM  (n=10; 1.84 ± 0.30) (fig.19J, #ρ<0.05, one-way ANOVA followed by 
Dunnett's Multiple Comparison Test). In figure 19I, it  is possible see that in LRRK2-IN-1 0.3 
µM there is a significant difference before and after perfusion with sucrose compared with 
cells no treated with LRRK2-IN-1. Although there is no straight forward explanation for this 
observation, these measurements in hippocampal cells were done with 2 days longer in 
culture which may explain this result. On the other hand, when the number of sEPSCs is 
expressed as sucrose/control ratio, the effect observed in cells treated with 0.3 µM  LRRK2-
IN-1 is situated in between 0.1 and 1 µM of the compound (fig. 19J).
Together with number of sEPSC, we evaluated the frequency of these events and cells 
treated with LRRK2-IN-1 at 0 µM (n=15; control, 18.98 ± 4.05; sucrose, 35.37 ± 6.43), 
LRRK2-IN-1 at  0.1 µM  (n=10; control, 20.54 ± 2.48; sucrose, 42.47 ± 6.53) and LRRK2-
IN-1 at 0.3 µM (n=10; control, 20.90 ± 3.65; sucrose, 37.24 ± 6.74) demonstrated an increase 
in the frequency after perfusion with sucrose. In cells treated with LRRK2-IN-1 at 
concentration of 1 µM  (n=10; control, 12.19 ± 3.02; sucrose, 15.21 ± 4.31), sucrose was 
unable to promote a significant increase in frequency (fig.19K, *ρ<0.05, two-tailed Student’s 
t test). The analysis of the ratio of frequency at different LRRK2-IN-1 concentrations (0 µM 
(n=15; 2.63 ± 0.47), at 0.1 µM  (n=15; 2.11 ± 0.27), 0.3 µM  (n=10; 1.89 ± 0.13 and at 1 µM 
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(n=10; 1.31 ± 0.17)) (fig.19L, #ρ<0.05, one-way ANOVA followed by Dunnett's Multiple 
Comparison Test) shows that only  in cells treated with 1 µM  LRRK2-IN-1 there is a 
significant different when compared with cells no treated with LRRK2-IN-1. Nevertheless, 
with two-away ANOVA statistics test is possible to see that there is a trend towards a 
concentration-dependent effect.
Lastly, we measured the peak amplitude of all events to evaluate if the compound has 
an effect in the post-synaptic cell. As, we predicted the LRRK2 kinase inhibition with 
LRRK2-IN-1 (0 µM: n=15; control, -22.69 ± 2.76; sucrose, -26.18 ± 3.68); (0.1 µM: n=10; 
control, -20.10 ± 1.61; sucrose, -24.10 ± 3.78); (0.3 µM: n=10; control, -17.27 ± 0.77; 
sucrose, -19.16 ± 0.99); (1 µM: n=10; control, -18.66 ± 1.93; sucrose, -22.27 ± 3.90) did not 
have an effect in peak amplitude at any concentration in control or in sucrose conditions (fig. 
19M). That was quantified by the ratio sucrose/control and it is possible that the variation is 
about 1 (0 µM; (n=15; 1.14 ± 0.05), 0.1 µM  (n=10; 1.19 ± 0.14), 0.3 µM (n=10; 1.12 ± 0.05) 
and 1 µM  (n=10; 1.18 ± 0.13) for all concentrations, which means that there is no change in 
post-synaptic cells (fig. 19N).
These results suggest that LRRK2 kinase activity  is involved in the regulation of 
endocytosis of synaptic vesicles and subsequent neurotransmission.
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5. Discussion
In light of the presented data, we suggest that LRRK2 kinase activity is important in 
the regulation of endocytosis of synaptic vesicles.
LRRK2 had been suggested as an important protein in pre-synaptic vesicular 
trafficking [13, 80] and in neurotransmitter release [70] but the molecular mechanism 
involved was unclear. The host lab in collaboration with Prof. Bart De Strooper’s and Prof. 
Patrik Verstreken’s group found that LRRK2 phosphorylates endophilin A1 at S75 residue, a 
residue located in the helix1 appendage of the BAR-domain, as described in the hypothesis 
earlier. This domain is crescent-shaped, binds lipid membranes to remodel their structure and 
coordinates CCP neck constriction (to mediate CCP fission from the plasma membrane, 
crucial features of endocytosis. The absence of this phosphorylation (by absence or inhibition 
of LRRK2) promotes the attachment of endophilin to the membrane, blocking SH3-driven 
recruitment, of dynamin and synaptojanin (both needed for in uncoating), leading to 
impairments in endocytosis (Matta et 2012 – manuscript accepted). This lack of 
phosphorylation together with lack on interactions with AP-2 complex subunits, NSF and 
Rab5, by  absence of LRRK2, may explain the results obtained in figure 17 [13]. The 
hypertonic sucrose was unable to increase the number of sEPSC and frequency  in LRRK2 KO 
cells while this increase could be observed in WT cells (see ratio figure 17). In fact the 
differences were only observed in presence of hypertonic sucrose, showing that hypertonic 
sucrose was a good approach to study endocytosis dependence of synaptic vesicle release [13, 
174]. This is the reason why we did not use TTX. TTX is a potent neurotoxin, frequently used 
to suppress neuronal activity  in cell culture by blockade of action potentials. This neurotoxin 
binds to the voltage-gated Na+ channels and fast Na+ channels in presynaptic cell, preventing 
the uptake of Na+ and, as consequence, the entrance of Ca2+ in nerve terminal. The blockade 
of action potential propagation impairs all the synaptic vesicle cycle, by  decreasing the ratio 
of recycling SV and the fusion of synaptic vesicles derived from recycling and reserve pool 
[13].
In control condition, RRP is the major pool involved in the basal activity, conferring 
the same results in both genotypes being released by  hypertonic sucrose stimulation. The 
small increases observed in control in number of sEPSC and frequency in LRRK2 KO cells 
may be attributable to an adaptive activity in docking or priming, conferring a higher 
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probability  to contact the membrane and fuse [175, 176] or a higher expression of a 
homologous LRRK2, LRRK1 leading to compensatory mechanisms.
Despite the small increase (not significant) in frequency in LRRK2 KO neurons (fig. 
17C, G) and decrease shown by  LRRK2 KO neurons in peak amplitude in both conditions 
(fig. 17 I,J), these results suggest that LRRK2 acts in presynaptic cell by controlling a pool of 
SV larger than the RRP [13]. The latter observation is supportive for the hypothesis that 
LRRK2 acts presynaptic. One possible explanation for the overall decrease in amplitude in 
LRRK2 KO neurons is that there are less SV available because the recycling machinery is 
impaired. The small amount of SV is not enough to maintain the same response, decreasing 
the peak amplitude in both conditions (fig. 17I ; #ρ=0.08 in control and *ρ<0.05 in sucrose) 
[13].
As LRRK2 has been suggested as a protein involved in presynaptic mechanisms, the 
previous results can be explained by impairments in exocytosis. In fact, together with proteins 
involved in endocytosis, LRRK2 has been described to interact with proteins involved in 
exocytosis like SNAP-25, syntaxin 1, proteins of SNARE complex [13, 78]. Given these 
evidences, we asked whether interference with dynamin1 function could mimic the effect 
observed in LRRK2 KO neurons. Dynasore is often used to study  the endocytosis by blocking 
the GTPase activity  of dynamin. Cells treated with vehicle (DMSO, 0.2%) (fig. 18) show the 
same result presented in figure 17. This shows that DMSO, a lipophilic solvent, at 0.2%, does 
not have an effect in the number of neurotransmitter release, frequency or peak amplitude in 
control or sucrose. However, during the experiments, the percentage of patched cells was 25% 
lower which might be explained by lipophilicity of DMSO that disturbs the cell membrane, 
and consequently  the stability  of gigaseal. In cells treated with dynasore, this compound did 
not alter the peak amplitude but increased the number of sEPSC in WT and LRRK2 KO cells 
in control and sucrose such as frequency in WT in both conditions (fig 18 C, D, G, H, I, K). 
Despite that, in presence of dynasore, sucrose was unable to induce the same effect showed 
by WT cells treated with vehicle (fig. 18K, L). If we consider, that the block of dynamin, 
prevents the recovery of synaptic vesicle membrane after transmitter release, this results in an 
accumulation of SV membrane in cell membrane, increasing the capacitance [Cin=Cm(4πa2)]
36  of the cell. In other words, the cell size and nerve terminal increase, and possibly more 
vesicular Ca2+ channels are in cell membrane, facilitate the formation of new Ca2+ channels 
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36 Cm = specific capacitance per unit are of all biological membranes, has the same value, approximately 1 µF cm-2 of membrane. Cin= total input capacitance of a 
spherical cell. a= area (cm2)
clusters. This induces a flow of current to the cell to produce the same change in membrane 
potential [161, 172, 173]. These vesicular Ca2+ channels [177, 178] allow the entrance of Ca2+ 
increasing the SV synthesis and increasing spontaneous release even in the absence of nerve 
stimulation. Other possibility, that might contribute to dynasore effects on transmitter release, 
is calcium-independent mechanism, but without conclusive results. The theory is based in that 
the dynamin and its blockade alter the many protein–protein interactions and it  has an impact 
in exocytosis. In high-frequency, the interaction of syndapins, which is important in actin 
cytoskeletal alterations, and in the synaptic vesicle cycle, with dynamin I [179] can be altered 
by dynasore, since dynasore interferes with the stability  of actin [180], altering the 
neurotransmitter release. These observations indicate that the time of exposition to dynasore 
did probably  not allow a good evaluation of dynamin1 inhibition. In a next experiment, 
increase in time of exposition, around 15 min or 30 min, should avoid the observed increase 
in number of sEPSC in both genotypes and in frequency of WT hippocampal cells. In terms of 
concentration, we think that this was well chosen, since that at this concentration, dynasore 
blocks 80% of dynamin and LRRK2 does not block the endocytosis completely [172].
Regarding the effects of dynasore in endocytosis, these observations suggest that the 
impairment caused by absence of LRRK2 is mimicked by blockade of dynamin with dynasore 
at 40 µM, which indicates that the impairment caused by absence of LRRK2 is at the 
endocytosis level. This idea is supported by role of endophilin (endophilin cycle). This protein 
has been suggested to play a role in two main roles in endocytosis: formation of pit 
(membrane invagination) and recruitment of adaptors proteins like AP-2, dynamin, 
amphiphysin, and AP180 to promote the membrane curvature in the 1st step of endocytosis 
(described above); and in recruitment of dynamin (5th step), amphiphysin, auxilin SNX9 and 
synaptojanin, to facilitate pinching off (scission) and the uncoating of CCV. Blocking the 
dynamin with dynasore, would arrest the cycle in the 5th step (dynamin is the main protein to 
execute this step, which is important for construction of the vesicle neck) impairing the 
endocytosis in U-shaped pit and in the stage where the neck needs to be “broken”, impairing 
the endocytosis in O-shaped-pit [181]. This causes that CCVs not to be formed completely or 
remains attached to the cell, leading to less synaptic vesicles available to release, which leads 
a less number of sEPSC detected and a decrease in the frequency  (increasing the time to 
complete the synaptic vesicle cycle). Although in LRRK2 KO hippocampal cells the effect in 
frequency is not exacerbating by dynasore exposure, it  can be attributable to the fact  there is 
impairment in recycling machinery [161].
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Finally, we also tested in rodent brain if the phosphorylation described in hypothesis is 
dependent of LRRK2 kinase activity. Inhibition of LRRK2 using LRRK2-IN-1 [142] results 
in pre-synaptic but not post-synaptic defects, similar to those found in LRRK2 KO cells with 
and without dynasore. The changes in peak amplitude are not significant but  it is possible to 
observe that since LRRK2-IN-1 at  0.1 µM, there is a decrease in evoked change by  sucrose in 
number of sEPSC when compared with cells not treated. But in terms of frequency, the 
analysis with two-away ANOVA statistics test shows that this inhibition by LRRK2-IN-1 
displays a dose dependent effect. Thus, and in our understanding, inhibition of LRRK2 kinase 
activity results in defects on sEPSC frequency due to synaptic vesicle recycling defects. This 
effect is likely due to reduced phosphorylation of the LRRK2 substrate Endophilin A. In fact, 
in this host lab, we found that the treatment with LRRK2-IN-1 at 1 µm switches the sub 
cellular localization of endophilin from to cytosol to cell membrane by reducing the 
phosphorylation of endophilin A as was hypothesized. This evidence supports the data shown 
in this work and that LRRK2 acts at endocytosis of synaptic vesicles (unpublished data). 
Nevertheless, it remains to be clarified whether more proteins phosphorylate endophilin A and 
if these proteins are inhibited by LRRK2-IN-1. Although LRRK2-IN-1 is claimed to be 
selective for LRRK2 [142] our inhibition experiment needs to be done in LRRK2 KO neurons 
as a negative control to LRRK2-IN-1. Furthermore, further studies with a selective GTPase 
inhibitor for LRRK2 would be useful to elucidate if endophilin phosphorylation is only  kinase 
dependent since the two enzymatic activities of LRRK2 regulate its own activity and 
impairments in each enzymatic activity causes variations in all LRRK2 activity [13, 78, 118].
In fact, using of GTPase inhibitor may also reveal a good therapeutic target since 
mutations in Roc domain also cause impairments in diverse pathways. In neurotransmission, 
the knock in of R1441C mutation in LRRK2, shows defects in DAergic neurotransmission in 
brain slices from substantia nigra [70].
More recently  a study has been described that LRRK2 interacts with tau protein [131]. 
As Tau protein, a risk factor for PD as well, is involvement in neurite outgrowth, this 
interaction suggests that LRRK2 affects the spines formation, via Tau interaction, and 
together, the two proteins may  have a role in synaptic transmission [131]. In fact, in 
Drosophila melanogaster, LRRK2 has been described as an important protein for synaptic 
morphogenesis and neurotransmission, via interaction with microtubules where tau has an 
important in maintenance of spines and neurites, transport of synaptic vesicles and 
maintenance of neurotransmission. Despite that, the regulation of these two synaptic 
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phenomena involves different mechanisms and pathways. It is also possible that  LRRK2 may 
have an effect in post-synaptic cell since it has been described an interaction with 4E-BP at 
the post-synapse, but only in studies with LRRK2 mutants because the studies through WT vs 
LRRK2 KO comparison, like this presented work is not possible to see any observable 
phenotype [126, 130].
The fact that the main mutations that have been shown to segregate with PD are 
located in the enzymatic domains of LRRK2 (G2019S (kinase domain) and R1441C/H/G 
(Roc domain)), suggest an altered enzymatic activity  drives LRRK2-dependent  pathology. 
Given the correlation described in this study  and manuscript accepted from Matta et al., 2012, 
these results will stimulate further studies mainly in determination whether perturbed 
endocytosis may contribute to PD.
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6. Conclusions
 The results presented in this work reveal that use of sucrose was a good strategy to 
study the role of LRRK2 in endocytosis. In presence of this sugar at 50 mM was possible 
observe that LRRK2 KO impairs the neurotransmission, by disrupt the endocytosis. Taking in 
account, the papers of Macia et al., 2006 [160], Douhitt et al., 2011 [161] and Chung et al., 
2010 [173] that describe the use of dynasore as a good approach to study endocytosis, the 
time of exposition (5 min) was not the most correct in this study. Further experiments need to 
be done with more time of treatment (30 min) and that possible, would decrease the 
misleading in total values.
 Regarding the experiment with LRRK2-IN-1 it is possible to conclude that only  at 1 
µM (treatment for 1h), LRRK2 kinase activity is full inhibited and that kinase activity is 
essential to endocytosis. At this concentration there was a significant decrease in number of 
sEPSC and frequency, mimicking the effect of LRRK2 absence.
Towards this work, the major conclusion is that the LRRK2 protein, via the kinase 
activity, plays an essential role in neurotransmission, at the level of endocytosis of synaptic 
vesicles. These findings need to be complemented with further studies in cultured primary 
neurons (hippocampal and striatal neurons) and animal models to advance our understanding 
in the physiological and pathophysiological role of LRRK2. The whole-cell patch clamp is a 
good technique to study the exocytosis and endocytosis but this approach need to be 
complement with techniques such as fluorescence imaging (with FM1-43 dye), optical 
imaging of vesicle dynamics (overexpression of synaptopHluorin or vGLUT1-pHluorin) 
electron microscopy. In fact, using autaptic cultures, cells that are pre- and post-synaptic cells 
itself, allow, via whole-cell patch clamp a better control in evoked release, in frequency of 
stimulation, evaluate the kinetics of the different  pools of vesicles and a large understanding 
on role of LRRK2 at  endocytosis of synaptic vesicles. Disease-associated mutations or 
LRRK2 KO alter enzymatic activity in vitro but also induce phenotypes in cultured neurons in 
a kinase-dependent and occasionally a GTPase dependent manner. It will be important to 
clarify whether kinase inhibition represents a feasible strategy for attenuating LRRK2-
dependent dopaminergic neurodegeneration (by impairments in neurotransmission-
endocytosis), or it is necessary include GTPase inhibitors as strategy to PD.
In fact, a complete understanding of LRRK2 function and the pathogenic mechanisms 
of familial mutations will offer a number of opportunities for the identification of novel 
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molecular targets which might prove useful for attenuating LRRK2-dependent 
neurodegeneration in PD.
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8. Attachments
83
Table: Summary of all proteins that have a role in CME according to function: core components, cargo-specific 
adaptors, inositol-5-phosphatases, kinases,  actin nucleation at clathrin-coated vesicles and other proteins with 
different functions or not clear function in CME. AAK1, AP2‑associated kinase 1; AGFG1, ARFGAP with FG 
repeats 1; ANTH, AP180 amino-terminal homology domain; AP2, adaptor protein 2; ARH, autosomal recessive 
hypercholesterolaemia; ASH, ASPM1–SPD2–hydin; CALM, clathrin assembly lymphoid myeloid leukaemia; 
CLT, clathrin light chain; CVAK104, coated vesicle associated kinase of 104 kDa; DAB2, Disabled homologue 
2; DYRK1A, dual-specificity Tyr phosphorylation-regulated kinase; EH, EPS15 homology; ENTH, epsin N-
terminal homology domain; EPS15, EGFR pathway substrate 15; EPS15R, EPS15‑related; FCHO, FCH domain 
only; GAK, cyclin G-associated kinase; GAP, GTPase-activating protein; GED, GTPase effector domain; GEF, 
guanine nucleotide exchange factor; GPCR, G protein-coupled receptor; HIP1, huntingtin-interacting protein 1; 
HIP1R, HIP1‑related; HSC70, heat shock cognate 70; LDLR, low-density lipoprotein receptor; NECAP, adaptin 
ear-binding coat-associated protein; OCRL, oculocerebrorenal syndrome of Lowe; PH, pleckstrin homology; 
PICALM, phosphatidylinositol-binding CALM; PRD, Pro-rich domain; PTB, phosphotyrosine binding; PTEN, 
phosphatase and tensin homologue; PX, phox homology; SAC1, suppressor of actin; SAM, sterile α-motif; 
SGIP1, SH3‑containing GRB2‑like 3‑interacting protein 1; SH, SRC homology; SHIP2, SH2 domain-containing 
inositol phosphatase 2; SNAP91, synaptosomal-associated protein 91 kDa homologue; SNX9, sorting nexin 9; 
TfR, transferrin receptor; TTP, TfR trafficking protein; UIMs, ubiquitin-interacting motifs; VAMP7, vesicle-
associated membrane protein 7. *Clathrin-binding motifs are denoted by a red dot. ‡Denotes the proteins for 
which the structure is depicted in the domain architecture column. §AP180 is the brain-specific protein, CALM 
is the ubiquitous one. ||Auxilin is the brain-specific protein, GAK is the ubiquitous one. Lipid binding module of 
undefined character. Table removed from McMahon and Boucrot -(2011) [154]
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